News and publications

Biotest Press releases

285 Press releases
Filter:
14.08.2017

News: Biotest AG: Biotest reported sales of EUR 247.1 million in the first half of 2017

Biotest reported sales of EUR 247.1 million in the first half of 2017 - Successful building inspection of the new building at Dreieich - Closing of the Public Takeover Offer is subject to the regulatory approval of the US foreign investment authority and of the Turkish antitrust authority Dreieich 14 August 2017. In the first half of 2017 the Biotest Group generated ...

Further information
2017 CORPORATE
19.07.2017

News: Biotest AG: Biotest takes over Cara Plasma s.r.o. with one plasma collection centre in the Czech Republic

Biotest takes over Cara Plasma s.r.o. with one plasma collection centre in the Czech Republic - Long-term plasma supplier Cara Plasma was taken over by Biotest - Biotest has now 16 plasma collection centres in Europe and - 22 stations in the USA for the strategic safeguarding of plasma supply Dreieich, 19 July 2017. Today, Biotest took over its long-time plasma supplier ...

Further information
2017 CORPORATE
22.06.2017

News: Biotest AG: Biotest reaches 2nd milestone in Biotest Next Level expansion project

Biotest reaches 2nd milestone in Biotest Next Level expansion project - Authorities grant building approval - Relocation activities of laboratories and offices for production start in June Dreieich, 22 June, 2017. Within the Biotest Next Level expansion project, Biotest will more than double its production capacity at the Dreieich site, invest over EUR 250 million and ...

Further information
2017 CORPORATE
14.06.2017

News: Biotest AG: Biotest AG shareholders accept voluntary public tender offer by CREAT Group

Biotest AG shareholders accept voluntary public tender offer by CREAT Group Dreieich, 14 June, 2017. The shareholders of Biotest AG have accepted the voluntary public tender offer by Tiancheng (Germany) Pharmaceutical Holdings AG, the bidding company controlled by CREAT Group, by fulfilling the minimum acceptance condition of 75 percent of Biotest ordinary shares ...

Further information
2017 CORPORATE
12.06.2017

PVR: Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification Acquisition/disposal of shares with voting rights X Acquisition/disposal of instruments Change of breakdown of voting rights X Other reason: Rejection of offer of shareholders to purchase shares outside ...

Further information
2017 PVR
07.06.2017

News: Biotest AG: Biotest sold US therapy business to ADMA Biologics, Inc.

Biotest sold US therapy business to ADMA Biologics, Inc. - Biotest receives 50% minus one share of ADMA - Biotest receives also distribution rights of specified current product and a right of first offer for the distribution of future products of ADMA for Europe, Near and Middle East and selected Asian countries Dreieich, 7 June 2017. Biotest's US subsidiary, Biotest ...

Further information
2017 CORPORATE
06.06.2017

PVR: Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification Acquisition/disposal of shares with voting rights X Acquisition/disposal of instruments Change of breakdown of voting rights Other reason: 3. Details of person subject to the notification ...

Further information
2017 PVR
01.06.2017

PVR: Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification Acquisition/disposal of shares with voting rights X Acquisition/disposal of instruments Change of breakdown of voting rights Other reason: 3. Details of person subject to the notification ...

Further information
2017 PVR
01.06.2017

PVR: Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification Acquisition/disposal of shares with voting rights X Acquisition/disposal of instruments Change of breakdown of voting rights Other reason: 3. Details of person subject to the notification ...

Further information
2017 PVR
01.06.2017

News: Biotest AG: Joint reasoned statement of Biotest AG - Management Board and Supervisory Board recommend to accept tender offer of CREAT Group

Joint reasoned statement of Biotest AG - Management Board and Supervisory Board recommend to accept tender offer of CREAT Group Dreieich, 1 June, 2017. Today, the Management Board and Supervisory Board of Biotest AG published their joint reasoned statement, pursuant to Section 27 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz - ...

Further information
2017 CORPORATE
24.05.2017

PVR: Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification Acquisition/disposal of shares with voting rights X Acquisition/disposal of instruments Change of breakdown of voting rights Other reason: 3. Details of person subject to the notification ...

Further information
2017 PVR
18.05.2017

News: Biotest AG: Publication of the offer document on the voluntary public tender for Biotest AG by CREAT Group

Publication of the offer document on the voluntary public tender for Biotest AG by CREAT Group - Offer document reaffirms the offer announced on April 7, 2017 - The Management Board and the Supervisory Board welcome and support the offer - The Management Board and the Supervisory Board will carefully review the offer document and issue a reasoned opinion pursuant to Section ...

Further information
2017 CORPORATE
17.05.2017

AFR: Biotest AG: Preliminary announcement of the publication of financial reports according to Articles 37v, 37w, 37y of the WpHG [the German Securities Act]

Biotest AG hereby announces that the following financial reports shall be disclosed : Report: Financial report (half-year/Q2) Date of disclosure / German: August 14, 2017 Date of disclosure / English: August 14, 2017 German: http://www.biotest.com/de/de/investor_relations/news_und_publikationen_/publikationen/quartalsberichte.cfm English: ...

Further information
2017 AFR
16.05.2017

News: Biotest AG: Biotest AG opens seventh plasma collection centre in Hungary

Biotest AG opens seventh plasma collection centre in Hungary - 15 plasma collection centres in Europe and - 22 in the US to ensure long-term plasma supply Dreieich, 16 May 2017. Biotest received an operating permit for its seventh plasma collection centre in Hungary from the country's national public health authority OTH. The centre is located in the second largest ...

Further information
2017 CORPORATE
10.05.2017

News: Biotest AG: Biotest reports revenue of EUR 110 million in the first quarter 2017

Biotest reports revenues of EUR 110.5 million in the first quarter 2017 Dreieich, 10 May 2017. In the first quarter of 2017, the Biotest Group generated sales of EUR 110.5 million, after EUR 133.6 million in the same period of the previous year. This corresponds to a percentage decrease of 17.3 %. EUR 26.5 million of this decrease is attributable to sales reductions from the ...

Further information
2017 CORPORATE
04.05.2017

PVR: Correction of a release from 07.04.2017, 15:23 CET/CEST - Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Correction of a notification of Major Holding published on 07.04.2017 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification Acquisition/disposal of shares with voting rights Acquisition/disposal of instruments Change of breakdown of voting rights X Other reason: Conclusion of ...

Further information
2017 PVR
28.04.2017

PVR: Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights Acquisition/disposal of instruments Change of breakdown of voting rights Other reason: 3. Details of person subject to the notification ...

Further information
2017 PVR
26.04.2017

News: Biotest AG: Voluntary recall of human albumin

Biotest: Voluntary recall of human albumin - Already quarantined batches of human albumin are recalled - Consequences of the one-time effect on Sales and EBIT are currently being evaluated - As a precaution, guidance is being reduced Dreieich, 26 April 2017 Today, Biotest has informed its customers about the recall of several batches of human albumin. The batches in ...

Further information
2017 CORPORATE
26.04.2017

Adhoc: Biotest AG: Biotest recalls human albumin and reduces forecast

Announcement according to Article 17 European Market Abuse Regulation (MAR) Biotest recalls human albumin and reduces forecast Dreieich, 26 April 2017. In close co-operation with regulatory authorities, Biotest performed a batch recall of human albumin (Albiomin(R)) 5% und 20% Biotest injection solution. The batches in question had already been quarantined by Biotest on 13 ...

Further information
2017 ADHOC
19.04.2017

News: Biotest AG: Biotest AG opens sixth plasma collection centre in Hungary

Biotest AG opens sixth plasma collection centre in Hungary - 14 plasma collection centres in Europe and - 22 in the US to ensure long-term plasma supply Dreieich, 19 April 2017. Biotest received an operating permit for its sixth plasma collection centre in Hungary from the country's national public health authority OTH. The centre is in the western Hungarian city ...

Further information
2017 CORPORATE
13.04.2017

News: Biotest AG: Biotest informs about limited availability of albumin

Biotest informs about limited availability of albumin - Due to an equipment failure the availability of albumin is currently limited - Consequences on sales and annual results are currently not assessable Dreieich, 13 April 2017 Today, Biotest has started to inform its customers about an expected albumin supply shortage within the coming months. This is due to an equipment ...

Further information
2017 CORPORATE
13.04.2017

PVR: Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights Acquisition/disposal of instruments Change of breakdown of voting rights Other reason: 3. Details of person subject to the notification ...

Further information
2017 PVR
11.04.2017

PVR: Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights Acquisition/disposal of instruments Change of breakdown of voting rights Other reason: 3. Details of person subject to the notification ...

Further information
2017 PVR
11.04.2017

PVR: Correction of a release from 06.04.2017, 14:54 CET/CEST - Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Announcement JO HAMBRO Capital Management Limited informed us that they retract their notification published by us on 6h April 2017, as no thresholds had been crossed which are relevant for ...

Further information
2017 PVR
07.04.2017

PVR: Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification Acquisition/disposal of shares with voting rights Acquisition/disposal of instruments Change of breakdown of voting rights X Other reason: Conclusion of irrevocable undertaking agreement ...

Further information
2017 PVR
07.04.2017

News: Biotest AG: Biotest AG and Creat enter into Business Combination Agreement

Biotest AG and Creat enter into Business Combination Agreement - Chinese strategic investor Creat to make a voluntary public takeover offer - Shareholders will be offered EUR 28.50 in cash per Biotest ordinary share and EUR 19.00 in cash per Biotest preference share - Offer represents a premium of 55% per ordinary share and 15% per preference share to the three month volume ...

Further information
2017 CORPORATE
07.04.2017

Adhoc: Biotest AG: Takeover Offer: Chinese strategic investor Creat to make a voluntary public takeover offer for the shares of Biotest AG

Announcement according to Article 17 European Market Abuse Regulation (MAR) Takeover Offer: Chinese strategic investor Creat to make a voluntary public takeover offer for the shares of Biotest AG Dreieich, 7 April 2017. Biotest AG, Tiancheng International Investment Limited, Hong Kong, and Blitz 17-623 AG (in future: Tiancheng (Germany) Pharmaceutical Holdings AG), ...

Further information
2017 ADHOC
06.04.2017

PVR: Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights Acquisition/disposal of instruments Change of breakdown of voting rights Other reason: 3. Details of person subject to the notification ...

Further information
2017 PVR
29.03.2017

Adhoc: Biotest AG: Discussions regarding business combination

Announcement according to Article 17 European Market Abuse Regulation (MAR) Discussions regarding business combination Dreieich, 29 March 2017. Biotest Aktiengesellschaft and Creat Group Corporation, a leading Chinese investment group, are currently in discussions regarding a potential business combination. Creat is a long-term strategic investor. Creat Group Corporation ...

Further information
2017 ADHOC
29.03.2017

News: Biotest AG: Discussions regarding possible business combination

Discussions regarding possible business combination Dreieich, 29 March 2017. Biotest AG announced today that it is in discussion with Creat Group Corporation (Creat), a leading Chinese investment group, regarding a potential business combination. Creat is a long-term strategic investor. Creat has indicated certain key parameters of a potential combination to be implemented ...

Further information
2017 CORPORATE
24.03.2017

News: Biotest AG: ImmunoGen has elected not to exercise its late stage co-development option for the US-Market with Biotest's antibody-drug conjugate (BT-062)

ImmunoGen has elected not to exercise its late stage co-development option for the US-Market with Biotest's antibody-drug conjugate (BT-062) - License agreement with ImmunoGen will continue Dreieich, 24 March 2017. Since 2006 a collaboration and licensing agreement between Biotest and ImmunoGen, Inc., MA (USA) (ImmunoGen) is in place for the use of ImmunoGen's antibody-drug ...

Further information
2017 CORPORATE
01.03.2017

News: Biotest AG: Recombinant clotting factor VIII with the name Vihuma(R) approved

Recombinant clotting factor VIII with the name Vihuma(R) approved - Market launch in Germany end of April 2017 - Vihuma(R) is a 4th generation recombinant human factor VIII preparation from a human cell line - Vihuma(R) is an optimal portfolio supplement for Biotest Dreieich, 1 March 2017. Today, the European Commission (EC) has approved the first, 4th ...

Further information
2017 CORPORATE
17.02.2017

News: Biotest AG: Proceedings against Biotest AG have been closed

Proceedings against Biotest AG have been closed Dreieich, 17 February 2017. Biotest AG has agreed with the Frankfurt public prosecution on a mutual termination of the proceedings against the company due to the Russia business. Besides the tax payment already communicated on 4 November 2016, Biotest has paid a corporate fine in the amount of EUR1.0 million. ...

Further information
2017 CORPORATE
16.02.2017

News: Biotest AG: EUR 64.4 million operating profit in core business of Biotest

EUR 64.4 million operating profit in core business of Biotest Dreieich, 16 February 2017. In line with the strategic realignment Biotest has restructured its US Therapy business. In the next years Biotest will focus in the US primarily on the plasma collection business and extend this business. Through the cooperation with ADMA Biologics Inc. Biotest will have access to new ...

Further information
2017 CORPORATE
27.01.2017

PVR: Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights Acquisition/disposal of instruments Change of breakdown of voting rights Other reason: 3. Details of person subject to the notification ...

Further information
2017 PVR
25.01.2017

News: Biotest AG: First patient treated in the next clinical phase III study of IgG Next Generation in the indication Primary Immune Thrombocytopenia (ITP)

First patient treated in the next clinical phase III study of IgG Next Generation in the indication Primary Immune Thrombocytopenia (ITP) - Study no. 992 is the second pivotal phase III study in the clinical program for IgG Next Generation, a novel development of our polyvalent immunoglobulin G - Study design was agreed with European regulatory authorities ...

Further information
2017 CORPORATE
23.01.2017

News: Biotest AG: Biotest to sell US therapy business to ADMA Biologics, Inc., and will receive approximately 50% of the shares of ADMA Biologics, Inc. at closing, which is anticipated to occur in the first half of 2017.

Biotest to sell US therapy business to ADMA Biologics, Inc., and will receive approximately 50% of the shares of ADMA Biologics, Inc. at closing, which is anticipated to occur in the first half of 2017. - Earnings before interest and taxes of Continued Operations in 2016 increases by approx. EUR30 million - Biotest secures participation in future success of ADMA ...

Further information
2017 CORPORATE
23.01.2017

Adhoc: Biotest AG: Biotest to sell US therapy business to ADMA Biologics, Inc. receiving approximately 50% of the shares of ADMA Biologics, Inc

Announcement according to Article 17 European Market Abuse Regulation (MAR) Biotest to sell US therapy business to ADMA Biologics, Inc. receiving approximately 50% of the shares of ADMA Biologics, Inc Dreieich, 23 January 2017. Biotest's US subsidiary, Biotest Pharmaceuticals Corporation, Boca Raton, Florida, USA, (BPC), has entered into a definitive agreement with ADMA ...

Further information
2017 ADHOC
06.12.2016

News: Biotest AG: Encouraging data of Indatuximab Ravtansine (BT-062) in combination therapy in advanced Multiple Myeloma

Encouraging data of Indatuximab Ravtansine (BT-062) in combination therapy in advanced Multiple Myeloma - New data from BT-062 in combination therapy presented at 58th annual conference of the American Society of Hematology - Clinical benefit seen in large majority of patients with advanced multiple myeloma - Very good response achieved in patients who did not ...

Further information
2016 CORPORATE
01.12.2016

News: Biotest AG: Biotest opens new plasma collection centre in Kearney, Nebraska, USA

Biotest opens new plasma collection centre in Kearney, Nebraska, USA - 13 plasma collection centres in Europe - 22 in the US to ensure long-term plasma supply Dreieich, 1 December 2016. Biotest Pharmaceuticals Corporation, Boca Raton, USA (BPC), a 100% subsidiary of Biotest AG, Germany, a leading manufacturer of plasma proteins and biological products, is pleased to ...

Further information
2016 CORPORATE
23.11.2016

News: Biotest AG: Biotest supports a large international retrospective study to record data on clinical use of Cytotect(R) after heart and lung transplantation

Biotest supports a large international retrospective study to record data on clinical use of Cytotect(R) after heart and lung transplantation - Results will provide a basis for design of a new transplantation study - Evaluation of the optimal treatment regimen as a basis for adapting international treatment guidelines - Marked medium-term increase of the market ...

Further information
2016 CORPORATE
10.11.2016

News: Biotest AG: Biotest increases revenues by 9%

Biotest increases revenues by 9% - EBIT increased to EUR 26.1 million - Cash flow of EUR 46.9 million - Guidance confirmed Dreieich, 10 November 2016. In the first nine months of 2016, the Biotest Group generated revenues of EUR 455.6 million, after EUR 417.9 million in the same period of the previous year. This corresponds to an increase of 9.0%. The largest sales ...

Further information
2016 CORPORATE
08.11.2016

News: Biotest AG: First patient treated in global clinical phase III study of IgG Next Generation in the indication Primary Immunodeficiency Disease (PID)

First patient treated in global clinical phase III study of IgG Next Generation in the indication Primary Immunodeficiency Disease (PID) - Study no. 991 marks the first phase III study in the worldwide clinical development program for IgG Next Generation, a novel development of our polyvalent immunoglobulin G - Study design was agreed with US and European ...

Further information
2016 CORPORATE
04.11.2016

Adhoc: Biotest AG: Altered tax assessments for 2005-2008 lead to a decrease of claims against Biotest AG - proceedings against Biotest AG are close to be completed

Announcement according to Article 17 European Market Abuse Regulation (MAR) Altered tax assessments for 2005-2008 lead to a decrease of claims against Biotest AG - proceedings against Biotest AG are close to be completed Dreieich, 4 November 2016. Today the Finanzamt Offenbach am Main (tax office Offenbach am Main) served to Biotest AG altered tax assessments for corporate ...

Further information
2016 ADHOC
03.11.2016

News: Biotest AG: Biotest AG will offer recombinant factor VIII from 2017

Biotest AG will offer recombinant factor VIII from 2017 - Cooperation with Octapharma for German-speaking markets - Fourth-generation recombinant human factor VIII preparation from a human cell line Dreieich, 3 November 2016. Biotest AG will be adding a recombinant factor VIII preparation to its haemophilia portfolio which will be produced by using a human cell ...

Further information
2016 CORPORATE
01.11.2016

News: Biotest AG: Interim analysis supports continuation of clinical phase IIa trial in Systemic Lupus Erythematosus (Study No. 990)

Interim analysis supports continuation of clinical phase IIa trial in Systemic Lupus Erythematosus (Study No. 990) - Independent Data Safety Monitoring Board (DSMB) recommends to start part 2 of clinical study No. 990 - DSMB did not identify any safety concerns - SLE is an indication with remaining high medical need Dreieich, 1 November 2016. Biotest AG ...

Further information
2016 CORPORATE
28.09.2016

News: Biotest AG: Biotest opens new plasma collection centre in Vermillion, South Dakota, USA

Biotest opens new plasma collection centre in Vermillion, South Dakota, USA - 13 plasma collection centres in Europe - 21 in the US to ensure long-term plasma supply Dreieich, 28 September 2016. Biotest Pharmaceuticals Corporation (BPC), Boca Raton, USA, a 100% subsidiary of Biotest AG, Germany, a leading manufacturer of plasma proteins and biological products, is ...

Further information
2016 CORPORATE
11.08.2016

News: Biotest AG: Biotest increases EBIT significantly

Biotest increases EBIT significantly - Strong EBIT increase to EUR 18.2 million vs. EUR 2.3 million - Increase of revenue by 6.4% to EUR 306 million - Operating Cash flow increased to EUR 50 million Dreieich, 11 August 2016. In the first half of 2016 the Biotest Group recorded revenue of EUR 306.1 million, representing an increase of 6.4% compared to the same period ...

Further information
2016 CORPORATE
03.08.2016

Adhoc: Biotest AG: Altered Tax Assessments for 2005 - 2008

Announcement according to Article 17 European Market Abuse Regulation (MAR) Altered Tax Assessments for 2005 - 2008 Dreieich, 3 August 2016. Today the Finanzamt Offenbach am Main (tax office Offenbach am Main) served to Biotest AG altered tax assessments for corporate tax, solidarity tax and trade tax for the years 2005 until 2008. The alterations are based on the ...

Further information
2016 ADHOC
29.07.2016

News: Biotest AG: Biotest AG opens fifth plasma collection centre in Hungary

Biotest AG opens fifth plasma collection centre in Hungary - Thirteen plasma collection centres in Europe and - Twenty in the US to ensure long-term plasma supply Dreieich, 29 July 2016. Biotest received an operating permit for its fifth plasma collection centre in Hungary from the country's national public health authority OTH. The centre is in the southern Hungarian ...

Further information
2016 CORPORATE
27.07.2016

News: Biotest AG: Biotest opens new plasma collection centre in Clemson, South Carolina, USA

Biotest opens new plasma collection centre in Clemson, South Carolina, USA - 12 plasma collection centres in Europe - 20 in the US to ensure long-term plasma supply Dreieich, 27 July 2016. Biotest Pharmaceuticals Corporation, Boca Raton, USA (BPC), a 100% subsidiary of Biotest AG, Germany, a leading manufacturer of plasma proteins and biological products, is pleased to ...

Further information
2016 CORPORATE
21.07.2016

PVR: Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification Acquisition/disposal of shares with voting rights Acquisition/disposal of instruments Change of breakdown of voting ...

Further information
2016 PVR
14.07.2016

News: Biotest AG: Former Biotest employee sentenced

Former Biotest employee sentenced Dreieich, 14 July 2016. Today, the Landgericht Darmstadt (District Court Darmstadt, Germany) sentenced a former Biotest representative for Russia to imprisonment of 5 years and 9 months. According to the judgement of the court, the former employee is guilty of complicity in fraud and tax evasion in the years 2007-2011. Her husband was sentenced ...

Further information
2016 CORPORATE
24.05.2016

News: Biotest AG: Biotest opens new plasma collection centre in Brookings, South Dakota, USA

Biotest opens new plasma collection centre in Brookings, South Dakota, USA - 12 plasma collection centres in Europe - 19 in the US to ensure long-term plasma supply Dreieich, 24 May 2016. Biotest Pharmaceuticals Corporation, Boca Raton, USA (BPC), a 100% subsidiary of Biotest AG, Germany, a leading manufacturer of plasma proteins and biological products, is pleased to ...

Further information
2016 CORPORATE
23.05.2016

News: Biotest AG: Pentaglobin(R) showed a significant survival benefit in severe infections caused by multidrug resistant bacteria

Pentaglobin(R) showed a significant survival benefit in severe infections caused by multidrug resistant bacteria - Additional therapy with Pentaglobin(R) significantly reduced the relative mortality risk by 33% in patients with confirmed resistance to antibiotics - Greatest relative survival benefit of 39% was seen in subgroup with infections by extensively ...

Further information
2016 CORPORATE
12.05.2016

News: Biotest AG: Annual general meeting approves payout of dividend

Biotest AG: Annual general meeting approves payout of dividend - Dividend payout of EUR 0.02 per ordinary share and EUR 0.04 per preference share Dreieich/ Frankfurt a. M., 12 May 2016. At the annual general meeting (AGM) held on 12 May 2016 in Frankfurt/ Main, shareholders of Biotest AG approved the payment of a dividend. With 74,4 percent of the ordinary share ...

Further information
2016 CORPORATE
12.05.2016

News: Biotest AG: Biotest increases EBIT significantly in the first quarter 2016

Biotest increases EBIT significantly in the first quarter 2016 - Increased Guidance confirmed - Good start of cooperation with Kedrion - Dividend proposed Dreieich, 12 May 2016. In the first quarter of 2016, the Biotest Group generated revenue of EUR 147.1 million, after EUR 142.5 million in the same period of the previous year. This corresponds to a percentage ...

Further information
2016 CORPORATE
07.04.2016

News: Biotest AG: Biotest AG opens fourth plasma collection centre in Hungary

Biotest AG opens fourth plasma collection centre in Hungary - Twelve plasma collection centres in Europe and - Eighteen in the US to ensure long-term plasma supply Dreieich, 7 April 2016. Yesterday, Biotest received an operating permit for its fourth plasma collection centre in Hungary from the country's pharmaceutical regulatory authority, OGYÉI. The centre is in the ...

Further information
2016 CORPORATE
23.03.2016

News: Biotest AG: Increase of guidance 2016 by more than 10%

Increase of guidance 2016 by more than 10% - Positive operating cash flow of EUR 38.1 million in 2015 - Equity ratio of 42.8% Dreieich, 23 March 2016. 2016. In the 2015 financial year, the Biotest Group generated revenues in the amount of EUR 589.6 million after EUR 582.0 million in the previous year. This corresponds to a 1.3 % increase. In the financial year 2015, ...

Further information
2016 CORPORATE
16.03.2016

News: Biotest AG: IgM Concentrate: Remarkable relative reduction in mortality of more than 50% in subgroup of patients

IgM Concentrate: Remarkable relative reduction in mortality of more than 50% in subgroup of patients - Favourable new data of phase II trial with IgM Concentrate in patients with severe Community Acquired Pneumonia (sCAP) published at ISICEM Symposium - Strong data justifies phase III development Dreieich, March 16, 2016. Biotest announces further results of a ...

Further information
2016 CORPORATE
11.02.2016

Adhoc: Biotest AG: Biotest exceeds EBIT guidance for 4th quarter 2015

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest exceeds EBIT guidance for 4th quarter 2015 Dreieich, 11. February 2016. According to preliminary and unaudited figures, the Biotest Group exceeds its EBIT guidance published in November 2015 in the amount of EUR 5-10 million for the fourth quarter 2015 and reports an EBIT of EUR 10.2 million in the ...

Further information
2016 ADHOC
11.02.2016

Adhoc: Biotest AG: Correction of the Ad hoc announcement dated February 11th 2016: Accidentally an incorrect preliminary and unaudited EBIT for the fiscal year 2015 was published. The EBIT amounts to EUR -71.8 million and not to EUR -72.3 million. Below, the corrected announcement:

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Correction of the Ad hoc announcement dated February 11th 2016: Accidentally an incorrect preliminary and unaudited EBIT for the fiscal year 2015 was published. The EBIT amounts to EUR -71.8 million and not to EUR -72.3 million. Below, the corrected announcement: Biotest exceeds EBIT guidance for 4th quarter ...

Further information
2016 ADHOC
19.01.2016

News: Biotest AG: Biotest enters into an exclusive cooperation agreement with Kedrion Biopharma for the distribution of Bivigam(R) in the U.S

Biotest enters into an exclusive cooperation agreement with Kedrion Biopharma for the distribution of Bivigam(R) in the U.S. - Kedrion Biopharma takes over the distribution of Bivigam(R) in the U.S. - U.S. production utilization will increase in 2016 - Earnings increase by USD 4-5 million in the first year Dreieich, January 19, 2016. Biotest Pharmaceuticals ...

Further information
2016 CORPORATE
14.01.2016

News: Biotest AG: Kreissparkasse Biberach continues to be major shareholder of Biotest

Kreissparkasse Biberach continues to be major shareholder of Biotest Dreieich, 14. January 2016. "Biotest has today published a notification of existing voting rights, pursuant to section 41, para. 4f of the German Securities Trading Act (WpHG) of the District of Biberach which submitted this notification controlling the Kreissparkasse Biberach ("KSK"). Even if this ...

Further information
2016 CORPORATE
14.01.2016

News: Biotest AG: Pentaglobin(R) showed encouraging results in the treatment of donor specific antibodies after lung transplantation

Pentaglobin(R) showed encouraging results in the treatment of donor specific antibodies after lung transplantation - In lung transplantation early new donor specific antibodies (DSA) are risk factors for mortality and graft rejection - Pentaglobin showed very good efficacy in patients who showed early DSA development after lung transplantation - Patients ...

Further information
2016 CORPORATE
14.01.2016

PVR: Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification Acquisition/disposal of shares with voting rights Acquisition/disposal of instruments Change of breakdown of voting ...

Further information
2016 PVR
12.01.2016

News: Biotest AG: Biotest receives approval in the European Union for the early use of Zutectra(R) after liver transplantation

Biotest receives approval in the European Union for the early use of Zutectra(R) after liver transplantation - Application of the subcutaneous hepatitis B hyperimmunoglobulin Zutectra(R) already one week after liver transplantation approved - Market position as a leading provider of hepatitis B hyperimmunoglobulins strengthened Dreieich, 12 January 2016. The ...

Further information
2016 CORPORATE
10.12.2015

News: Biotest AG: Successful start of the operation of the new plasma receiving area and the virological laboratories

Successful start of the operation of the new plasma receiving area and the virological laboratories - Authorities issue operating license for the building - Storage capacity for human plasma expanded to 1,440 pallet slots - Another milestone reached in the context of the Biotest Next Level capacity expansion programme Dreieich, 10 December 2015. After just two ...

Further information
2015 CORPORATE
01.12.2015

News: Biotest AG: Biotest proceeds into phase III programme in congenital fibrinogen deficiency

Biotest proceeds into phase III programme in congenital fibrinogen deficiency - Fibrinogen concentrate shows good efficacy and safety profile based on preliminary data - Preliminary data on pharmacokinetic profile are comparable to licensed products - German authority (Paul-Ehrlich-Institut) approved the extension of ongoing study to phase a I/III ...

Further information
2015 CORPORATE
30.11.2015

CMS: Biotest AG: Release of the Home Member State according to Article 2c of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Biotest AG announces according to Art. 2c WpHG that Germany is the Home Member State. 30.11.2015 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.medientreff.de and ...

Further information
2015 CMS
23.11.2015

News: Biotest AG: Biotest receives positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) for the early use of Zutectra(R) after liver transplantation

Biotest receives positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) for the early use of Zutectra(R) after liver transplantation - Market position as a leading provider of hepatitis B hyperimmunoglobulins strengthened - Biotest expects European approval in February 2016 Dreieich, 23 November 2015. The Committee for Medicinal ...

Further information
2015 CORPORATE
10.11.2015

News: Biotest AG: Biotest establishes basis for significantly higher earnings potentia

Biotest establishes basis for significantly higher earnings potential - Profitable core business despite setback in Q3 2015 - Focus on core business increases planning reliability - Good progress of plasma protein development projects Dreieich, 10 November 2015. At today's analyst conference in Frankfurt am Main, the Board of Management will discuss how the continued ...

Further information
2015 CORPORATE
09.11.2015

News: Biotest AG: Biotest to present data from TREAT 2b trial at The American College of Rheumatology (ACR) 2015 Annual Meeting

Biotest to present data from TREAT 2b trial at The American College of Rheumatology (ACR) 2015 Annual Meeting - Presentation of clinical results from TREAT 2b trial (T cell REgulating Arthritis Trial 2b), evaluating the efficacy, safety and tolerability of its investigational monoclonal antibody, Tregalizumab (BT-061), plus methotrexate combination therapy in ...

Further information
2015 CORPORATE
06.11.2015

News: Biotest AG: Letter to Shareholders

LETTER TO SHAREHOLDERS November 4, 2015 Dear Shareholders, The past weeks have been challenging for all of us. As you know, we announced impairments totalling EUR 84 million on 20 October 2015, resulting in negative EBIT of EUR -82 million for the first three quarters. Most of the impairments and write-downs relate to our US therapy activities. The US plasma collection business was not ...

Further information
2015 CORPORATE
20.10.2015

Adhoc: Biotest AG: Impairment of US business and change of guidance

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest: Impairment of US business and change of guidance Dreieich, 20 October 2015: Biotest AG announces to make impairments today totalling EUR84 million, leading to a negative third-quarter result (EBIT Q1-Q3 2015: -EUR82 million). The impairment primarily relates to the company's US Therapy activities, ...

Further information
2015 ADHOC
20.10.2015

News: Biotest AG: Impairment of US business and investments in Europe

Biotest: Impairment of US business and investments in Europe Dreieich, 20 October 2015. Biotest AG announces impairments today totalling to EUR 84 million, leading to a negative third-quarter result (Q1-Q3 2015 EBIT: EUR -82 million). The impairment primarily relates to the company's US therapy activities. The US plasma collection business remains unaffected. The expansion of ...

Further information
2015 CORPORATE
13.10.2015

PVR: Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

On October 13, 2015, ETHENEA Independant Investors S.A., Munsbach, Luxembourg has informed us according to Article 21, Section 1 of the WpHG that via shares its Voting Rights on Biotest AG, Dreieich, Germany, have exceeded the 3% threshold of the Voting Rights on July 15, 2015 and on that day amounted to 3.03% (this corresponds to 600000 Voting Rights). 13.10.2015 The DGAP Distribution ...

Further information
2015 PVR
06.10.2015

News: Biotest AG: Biotest reaches the next milestone in the clinical development of its monoclonal antibody BT-063 by starting the clinical phase IIa trial in the indication systemic lupus erythematosus (SLE)

Biotest reaches the next milestone in the clinical development of its monoclonal antibody BT-063 by starting the clinical phase IIa trial in the indication systemic lupus erythematosus (SLE) - First patient included and treated in the multicentric, placebo-controlled phase IIa trial - SLE is an indication with high medical need Dreieich, ...

Further information
2015 CORPORATE
30.09.2015

News: Biotest AG: Biotest AG continues cooperation with ADMA Biologics, Inc. for the RSV hyperimmunoglobulin RI-002

Biotest AG continues cooperation with ADMA Biologics, Inc. for the RSV hyperimmunoglobulin RI-002 - Biologic Licence Application submitted to Food and Drug Administration after successful phase III trial Dreieich, September 30, 2015. In accordance with the license agreement entered on December 31, 2012 Biotest AG (Biotest) made a milestone payment following ADMA ...

Further information
2015 CORPORATE
14.08.2015

PVR: Correction of a release from 14.08.2015, 11:11 CET - Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

On August 13, 2015, BayernInvest Kapitalverwaltungsgesellschaft mbH, 80333 Munich, Germany has informed us according to Article 21, Section 1 of the WpHG that via shares its Voting Rights on Biotest AG, Dreieich, Germany, have fallen below the 3% threshold of the Voting Rights on August 11, 2015 and on that day amounted to 2.46% (this corresponds to 487368 Voting Rights). 1.92% of Voting ...

Further information
2015 PVR
14.08.2015

PVR: Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

On August 13, 2015, Bayerininvest Kapitalverwaltungsgesellschaft mbH, 80333 Munich, Germany has informed us according to Article 21, Section 1 of the WpHG that via shares its Voting Rights on Biotest AG, Dreieich, Germany, have fallen below the 3% threshold of the Voting Rights on August 11, 2015 and on that day amounted to 2.46% (this corresponds to 487368 Voting Rights). 1.92% of Voting ...

Further information
2015 PVR
11.08.2015

News: Biotest AG: Biotest increases revenues in first half year 2015 by 8.9%

Biotest increases revenues in first half year 2015 by 8.9% - Clinical development of BT-061 will be discontinued - Capacity expansion at headquarter Dreieich on schedule - Board of management confirms EBIT guidance of EUR 20-25 million Dreieich, 11. August 2015. The Biotest Group recorded significant year-on-year sales growth in the first half of 2015. The Group ...

Further information
2015 CORPORATE
14.07.2015

News: Biotest AG: Biotest stock split becomes effective as scheduled - first trading day on July 15

Biotest stock split becomes effective as scheduled - first trading day on July 15 - Stock listing and shareholders' deposits will be changed on July 15th in a ratio 1:3 - Shares in security accounts will be converted automatically - Unexecuted orders will expire after July 14 Dreieich, 14 July 2015. The stock split with capital increase from company funds was ...

Further information
2015 CORPORATE
08.07.2015

News: Biotest AG: Biotest AG reorganises stock exchange listing due to share split on 15 July 2015

Biotest AG reorganises stock exchange listing due to share split on 15 July 2015 - Share split at a ration of 1:3 - By share split and capital increase from company's funds the shareholder structure will not change Dreieich, 8 July 2015. Biotest AG reorganises the stock exchange listing of its shares at a ratio of 1:3 due to the share split on 15 July ...

Further information
2015 CORPORATE
01.07.2015

News: Biotest AG: Biotest and CEVEC Pharmaceuticals enter into a License Agreement regarding a cell line system for the production of tailor-made proteins

Biotest and CEVEC Pharmaceuticals enter into a License Agreement regarding a cell line system for the production of tailor-made proteins - The agreement relates to CEVEC's proprietary cell line (expression system) for the development, production and commercialization of proteins to treat the symptoms of Haemophilia ...

Further information
2015 CORPORATE
30.06.2015

News: Biotest AG: Biotest's IgM Concentrate shows encouraging results in life-threatening pneumonia

Biotest's IgM Concentrate shows encouraging results in life-threatening pneumonia - Phase II trial with IgM Concentrate completed in patients with severe community acquired pneumonia (sCAP) requiring mechanical ventilation - Encouraging trend in reducing duration of ventilation as well as mortality Dreieich, June 30, ...

Further information
2015 CORPORATE
30.06.2015

NVR: Biotest AG: Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Biotest AG hereby announces that at the end of the month June 2015 the number of Voting Rights amounts to a total of 19785726 Voting Rights. It is planned that the technical execution will take place on July 15th, 2015. 30.06.2015 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.medientreff.de and ...

Further information
2015 NVR
24.06.2015

News: Biotest AG: Biotest regains rights to Tregalizumab (BT-061)

Biotest regains rights to Tregalizumab (BT-061) - AbbVie exercised its rights to opt-out of the worldwide license, development and commercialisation agreement Dreieich, June 24, 2015. Biotest AG today announced that AbbVie and Biotest will end their collaboration on the development and commercialisation of Tregalizumab (BT-061). AbbVie has exercised its ...

Further information
2015 CORPORATE
01.06.2015

News: Biotest AG: Biotest AG and Affibody AB enter into a Research License and Option Agreement regarding the Albumod(TM) technology platform

Biotest AG and Affibody AB enter into a Research License and Option Agreement regarding the Albumod(TM) technology platform - Affibody's Albumod(TM) technology is designed to prolong the duration of action of biopharmaceuticals and therefore potentially enhances the efficacy of biopharmaceuticals Dreieich, Germany and Solna, Sweden, 1 June 2015. Biotest AG and ...

Further information
2015 CORPORATE
07.05.2015

News: Biotest AG: Annual general meeting approves increase of dividend and a share split

Biotest AG: Annual general meeting approves increase of dividend and a share split - Dividend payment of EUR 0.60 per ordinary share and EUR 0.66 per preference share - Share split with the relation of one to three approved Dreieich/ Frankfurt a. M., 7 May 2015. At the annual general meeting (AGM) held on 7 May 2015 in Frankfurt am Main, shareholders of Biotest ...

Further information
2015 CORPORATE
07.05.2015

News: Biotest AG: Biotest increases revenues by 16,6%

Biotest increases revenues by 16,6% - Higher Sales in the US - Capacity expansion at headquarter Dreieich in schedule Dreieich, 7 May 2015. The Biotest Group again succeeded to increase revenues in the first three months of 2015. The Group generated revenue of EUR 142.5 million in the period from January to March 2015. This represents an increase of 16.6 % compared to ...

Further information
2015 CORPORATE
24.04.2015

News: Biotest AG: Biotest Phase IIb study of Tregalizumab (BT-061) in moderate to severe rheumatoide Arthritis did not meet the primary endpoint - potential one time effect of up to - EUR 30 million

Biotest Phase IIb study of Tregalizumab (BT-061) in moderate to severe rheumatoide Arthritis did not meet the primary endpoint - potential one time effect of up to - EUR 30 million - No safety concerns were noted for the BT-061 study - AbbVie, will decide within 90 days whether to continue the co-development on tregalizumab (BT-061) Dreieich, April 24, 2015 - ...

Further information
2015 CORPORATE
24.04.2015

Adhoc: Biotest AG: Biotest Phase IIb study of Tregalizumab (BT-061) in moderate to severe rheumatoide Arthritis did not meet the primary endpoint - potential one time effect of - EUR 30 million

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest Phase IIb study of Tregalizumab (BT-061) in moderate to severe rheumatoide Arthritis did not meet the primary endpoint - potential one time effect of - EUR 30 million Dreieich, April 24, 2015 - Biotest today announced top line results from the TREAT 2b study [T cell REgulating Arthritis Trial 2b], ...

Further information
2015 ADHOC
23.04.2015

News: Biotest AG: Biotest presents new clinical and preclinical results of Civacir(R) at The 50th International Liver Congress 2015 in Vienna

Biotest presents new clinical and preclinical results of Civacir(R) at The 50th International Liver Congress 2015 in Vienna - Preliminary clinical results suggest that Civacir(R) reduces the hepatitis C virus recurrence rate after liver transplantation in an impressive way to 5% (1 out of 21 patients) - Preclinical data shows activity of Civacir(R) against ...

Further information
2015 CORPORATE
23.04.2015

News: Biotest AG: Biotest proves effective protection from Hepatitis B virus reinfection after liver transplantation in 'ZEUS' study with subcutaneous hepatitis B immunoglobulin Zutectra (R)

Biotest proves effective protection from Hepatitis B virus reinfection after liver transplantation in "ZEUS" study with subcutaneous hepatitis B immunoglobulin Zutectra(R) - The Zutectra-Early-Use-Study (ZEUS) demonstrates safe and effective switch from high dose intravenous hepatitis B immunoglobulin (HBIG) to subcutaneous HBIG, Zutectra(R), at the earliest one ...

Further information
2015 CORPORATE
13.04.2015

News: Biotest AG: Biotest announces the opening of a plasma collection facility in Conway, Arkansas, US and the relocation of it's plasma collection Facility in San Antonio, Texas, US

Biotest announces the opening of a plasma collection facility in Conway, Arkansas, US and the relocation of it's plasma collection Facility in San Antonio, Texas, US - Total number of plasma collection centers in the US now eighteen. Dreieich, 13 April, 2015. Biotest is pleased to announce the addition of its newest plasma collection in Conway, Arkansas, US. The over ...

Further information
2015 CORPORATE
24.03.2015

News: Biotest AG: Biotest increases sales by 16.2%

Biotest increases sales by 16.2% - Earnings before interest and tax (EBIT) at EUR 53.4 million - Expansion project "Biotest Next level" in timeline and budget - Share split with the relation of 1:3 to be proposed at AGM on May 7th, 2015 Dreieich, 24 March 2015. The Biotest Group generated sales of EUR 582.0 million in the 2014 financial year. This amounts to a ...

Further information
2015 CORPORATE
17.03.2015

Adhoc: Biotest AG: Biotest AG: Biotest proposes capital increase from capital funds and share split to General Meeting

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest AG: Biotest proposes capital increase from capital funds and share split to General Meeting - Proposed capital increase without issuing new shares - Proposed share split with the relation of one to three Dreieich, 17 March 2015. Biotest AG will propose a capital increase from capital funds and ...

Further information
2015 ADHOC
10.03.2015

AFR: Biotest AG: Announcement according to Articles 37v, 37w, 37x et seqq. of the WpHG [the German Securities Act] with the objective of Europe-wide distribution

Biotest AG hereby announces that the following financial reports shall be disclosed : Report: Annual financial report Date of disclosure / German: March 24, 2015 Date of disclosure / English: March 24, 2015 German: http://www.equitystory.com/download/Companies/biotest/Annual%20Reports/EinzelabschlussBiotestAG2014.pdf English: ...

Further information
2015 AFR
23.02.2015

PVR: Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

On February 20, 2015, Deka Investment GmbH, Frankfurt am Main, Germany has informed us according to Article 21, Section 1 of the WpHG that via shares its Voting Rights on Biotest AG, Dreieich, Germany, have fallen below the 3% threshold of the Voting Rights on February 18, 2015 and on that day amounted to 1.85% (this corresponds to 121716 Voting Rights). 1.85% of Voting Rights (this ...

Further information
2015 PVR
13.02.2015

Adhoc: Biotest AG: Biotest increases revenues significantly by 16.2%

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest increases revenues significantly by 16.2% Dreieich, 13. February 2015. According to preliminary and unaudited figures, the Biotest Group increased revenues to EUR 582.0 million. This represents an increase of 16.2% compared to the previous year (EUR 500.8 million). Biotest successfully gained ...

Further information
2015 ADHOC
09.02.2015

News: Biotest AG:

Biotest opens another plasma collection center in the US - Biotest continues strengthening global plasma collection with a second plasma collection center in Jacksonville, North Caroline, US Dreieich, February 9, 2015. Biotest announces that Biotest Pharmaceuticals Corporation (BPC), a 100% subsidiary of Biotest AG, Dreieich, has opened a new plasma collection center ...

Further information
2015 CORPORATE
02.02.2015

PVR: Biotest AG: Publication according to § 26 paragraph. 1 WpHG with the objective of Europe-wide distribution

Universal-Investment-Gesellschaft mbH, 60486 Frankfurt, Germany has informed us according to Article 21, Section 1 of the WpHG that via shares its Voting Rights on Biotest AG, Dreieich, Germany, have fallen below the 3% threshold of the Voting Rights on January 23, 2015 and on that day amounted to 2.95% (this corresponds to 194702 Voting Rights). 2.95% of Voting Rights (this corresponds to ...

Further information
2015 PVR
09.12.2014

News: Biotest AG: Encouraging Efficacy of Indatuximab Ravtansine (BT-062) in Multiple Myeloma in combination with Lenalidomide and Dexamethasone

Encouraging Efficacy of Indatuximab Ravtansine (BT-062) in Multiple Myeloma in combination with Lenalidomide and Dexamethasone - New data from combination therapy study presented at 56th annual conference of the American Society of Hematology - Clinical benefit seen in all evaluable patients with advanced Multiple Myeloma - Complete remissions observed in ...

Further information
2014 CORPORATE
18.11.2014

News: Biotest AG: Biotest Presents New Preclinical Data on Tregalizumab (BT-061) at the Annual

Biotest Presents New Preclinical Data on Tregalizumab (BT-061) at the Annual Meeting of the American College of Rheumatology in Boston - New preclinical results confirm treatment rationale in mono- and combination therapy settings - Pro-inflammatory cytokines or methotrexate have no negative impact on in vitro activation of regulatory T-cells by ...

Further information
2014 CORPORATE
17.11.2014

News: Biotest AG: Managers of Italian Subsidiary have been charged with illegal price fixing

Managers of Italian Subsidiary have been charged with illegal price fixing Dreieich, November 17, 2014. In 2010 the public prosecutor of Naples had initiated investigations against numerous employees of various pharmaceutical companies and institutions and charged them with illegal price fixing. Besides the Director of Administration of the University of Naples and the owner ...

Further information
2014 CORPORATE
12.11.2014

News: Biotest AG: Biotest increases sales by 11,5% compared to previous yea

Biotest increases sales by 11,5% compared to previous year - Good interim results of R&D projects Civacir(R) and Tregalizumab (BT-061) - Building permission for capacity expansion in Dreieich granted Dreieich, 12 November 2014. The Biotest Group was able to further increase its pace of growth recorded in the first half of the year in the first nine months of 2014. ...

Further information
2014 CORPORATE
10.11.2014

News: Biotest AG: Very good results of Civacir(R) (Hepatitis C Immune Globulin) US Phase III clinical trial

Very good results of Civacir(R) (Hepatitis C Immune Globulin) US Phase III clinical trial - Preliminary data presented at the Congress of the American Association for the Study of Liver Disease (AASLD) show prevention of re-infection after liver-transplantation - More than 50% of study patients have been enrolled in the Civacir Phase III trial Dreieich, ...

Further information
2014 CORPORATE
05.11.2014

News: Biotest AG: Biotest receives marketing authorisation for Albiomin 20% in China

Biotest receives marketing authorisation for Albiomin 20% in China - Marketing approval granted for Albumin in China - The Chinese Pharmamarket is the second largest market for pharmaceuticals Dreieich, Germany, November 5 2014. Biotest has received the marketing authorization for Albiomin 20% (20% solution of human albumin) on October 31th, 2014 from the Chinese ...

Further information
2014 CORPORATE
24.10.2014

News: Biotest AG: Further preclinical studies emphasise the potential of Indatuximab Ravtansine (BT-062) in solid tumours

Further preclinical studies emphasise the potential of Indatuximab Ravtansine (BT-062) in solid tumours - Antibody-drug conjugate shows high efficacy in an animal model in the treatment of bladder, breast, pancreatic and other tumours. - Complete remission achieved in some treatment-refractory tumours. - Presentation of the results at the World ADC specialist ...

Further information
2014 CORPORATE
15.10.2014

Adhoc: Biotest AG: Search at Biotest - company rejects allegation

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Search at Biotest - company rejects allegations Dreieich, October 15, 2014. The Frankfurt Public Prosecution Office today once again executed a search at Biotest AG, Dreieich. The search is apparently based on the extension of the public prosecutors' investigations into the company's business with Russia, ...

Further information
2014 ADHOC
15.10.2014

News: Biotest AG: Search at Biotest - company rejects allegations

Search at Biotest - company rejects allegations - Accusations absolutely incomprehensible for Biotest AG - Proposal for clarification not accepted by public prosecutor Dreieich, October 15, 2014. The Frankfurt Public Prosecution Office has once again executed a search at Biotest AG, Dreieich. The search is apparently based on the extension of the public prosecutions' ...

Further information
2014 CORPORATE
09.09.2014

News: Biotest AG: Biotest completes recruitment in Phase IIb study (TREAT 2b) of Tregalizumab (BT-061) in patients with rheumatoid arthritis

Biotest completes recruitment in Phase IIb study (TREAT 2b) of Tregalizumab (BT-061) in patients with rheumatoid arthritis - Biotest's largest and most complex clinical study is running according to plan - Patient recruitment completed. More than 300 patients enrolled within the past ten months Dreieich, September 9, 2014. Biotest is pleased to announce that ...

Further information
2014 CORPORATE
11.08.2014

News: Biotest AG: Biotest increases revenues by 8,5%

Biotest increases revenues by 8,5% - EBIT increase by 2,3% - Good Progress in the R&D pipeline - Revised outlook Dreieich, August 11, 2014. The Biotest Group was again able to significantly increase revenues in the first half of 2014, recording growth of 8.5 % compared to the same period in the previous year. The Group generated revenues of EUR 264.1 million in the ...

Further information
2014 CORPORATE
11.08.2014

Adhoc: Biotest AG: Outlook revised

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Outlook revised Dreieich, August 11, 2014. The Management Board revises its outlook. A sales increase of 7% and an operating result (EBIT) slightly above the previous year is expected. Prior to this, an increase of 10% was planned for both key figures. Main reasons for the lower outlook: The recall and the ...

Further information
2014 ADHOC
09.07.2014

Adhoc: Biotest AG: Dr. Bernhard Ehmer to become new CEO of Biotest AG

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Dr. Bernhard Ehmer to become new CEO of Biotest AG Dreieich, 9 July 2014 - The Supervisory Board of Biotest AG, in its meeting today, has appointed Dr. Bernhard Ehmer (59) as member of the Executive Board effective November 1st, 2014. As of January 1st, 2015, Ehmer will take over the role as CEO from Prof. ...

Further information
2014 ADHOC
07.05.2014

News: Biotest AG: Biotest continues to show a sales increase

Biotest continues to show a sales increase - Sales at EUR 122.2 million (+2.9%) - Progress in CapEx program "Biotest Next Level" - Positive development in R&D projects Dreieich,7 May 2014. The Biotest Group was again able to increase sales in the first three months of the 2014 financial year. The Group generated revenues of EUR 122.2 million in the period under ...

Further information
2014 CORPORATE
07.05.2014

News: Biotest AG: : Annual general meeting approves again increase of dividend

Biotest AG: Annual general meeting approves again increase of dividend - Distribution of EUR 0.57 per ordinary share and EUR 0.63 per preference share Dreieich/ Frankfurt a. M., 7 May 2014. At the annual general meeting (AGM) held on 7 May 2014 in Frankfurt am Main shareholders of Biotest AG approved a payment of an increased dividend. With 78.0 percent of the ordinary ...

Further information
2014 CORPORATE
28.03.2014

PVR: Biotest AG: Correction of a release from March 27, 2014, 15:07 CET Publication according to § 26 paragraph. 1 WpHG with the objective of Europe-wide distribution

On March 26, 2014, Landkreis Biberach, Biberach, Deutschland has informed us according to Article 21, Section 1 of the WpHG that via shares its Voting Rights on Biotest AG, Dreieich, Deutschland, have fallen below the 20% threshold of the Voting Rights on March 25, 2014 and on that day amounted to 19.95% (this corresponds to 1315780 Voting Rights). 19.95% of Voting Rights (this corresponds to ...

Further information
2014 PVR
27.03.2014

News: Biotest AG: Biotest AG initiates clinical study with Indatuximab Ravtansine (BT-062) in solid tumors

Biotest AG initiates clinical study with Indatuximab Ravtansine (BT-062) in solid tumors - First patient treated in phase I/IIa study (no. 989) in patients with triple-negative metastatic breast cancer or metastatic urinary bladder cancer Dreieich, 27 March 2014. Biotest AG, pursuing an innovative technology using the antibody-drug conjugate indatuximab ravtansine ...

Further information
2014 CORPORATE
27.03.2014

PVR: Biotest AG: Publication according to § 26 paragraph. 1 WpHG with the objective of Europe-wide distribution

On March 26, 2014, Landkreis Biberach, Biberach, Deutschland has informed us according to Article 21, Section 1 of the WpHG that via shares its Voting Rights on Biotest AG, Dreieich, Deutschland, have fallen below the 20% threshold of the Voting Rights on March 25, 2014 and on that day amounted to 19.95% (this corresponds to 1315780 Voting Rights). 19.95% of Voting Rights (this corresponds to ...

Further information
2014 PVR
27.03.2014

PVR: Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

On March 26, 2014, Kreissparkasse Biberach, Biberach, Deutschland has informed us according to Article 21, Section 1 of the WpHG that via shares its Voting Rights on Biotest AG, Dreieich, Deutschland, have fallen below the 20% threshold of the Voting Rights on March 25, 2014 and on that day amounted to 19.95% (this corresponds to 1315780 Voting Rights). 27.03.2014 DGAP's Distribution ...

Further information
2014 PVR
25.03.2014

News: Biotest AG: Biotest increases profit after tax by 38.5 %

Biotest increases profit after tax by 38.5 % - Earnings before interest and tax (EBIT) of the Biotest Group at EUR53.8 million represents an increase of 20.4 % vs. the previous year - Revenue increase by 13.8 % Dreieich, 25 March 2014. In the 2013 financial year Biotest was again able to increase sales significantly by 13.8 % and exceeded the EUR 500 million mark ...

Further information
2014 CORPORATE
20.02.2014

Adhoc: Biotest AG: Biotest increases earnings after taxes by 38.5%

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest increases earnings after taxes by 38.5% Dreieich, 20. February 2014. According to preliminary and unaudited figures, the Biotest Group recorded earnings after tax (EAT) of EUR 32.0 million, an increase from EUR 23.1 million in 2012 by 38.5%. Earnings before taxes (EBT) increased by 31.0% to EUR 47.8 ...

Further information
2014 ADHOC
20.12.2013

News: Biotest AG: Biotest receives marketing authorisation for Albiomin(R) in Brazil and approval for commissioning of expanded albumin production

Biotest receives marketing authorisation for Albiomin(R) in Brazil and approval for commissioning of expanded albumin production - Marketing approval granted for albumin in Brazil - Albumin production capacity doubled from 21 to 42 tons in Dreieich, Germany Dreieich, Germany, 20 December 2013. Biotest Farmaceutica Ltda., Brazil, a 100% subsidiary of Biotest AG, has ...

Further information
2013 CORPORATE
10.12.2013

News: Biotest AG: Clinical Study with Indatuximab Ravtansine (BT-062) in Multiple Myeloma shows good Tolerability and encouraging Efficacy in Combination with Lenalidomide and Dexamethasone

Clinical Study with Indatuximab Ravtansine (BT-062) in Multiple Myeloma shows good Tolerability and encouraging Efficacy in Combination with Lenalidomide and Dexamethasone - Efficacy and tolerability data from combination therapy study 983 presented at 55th annual conference of the American Society of Hematology (ASH) - Good tolerability of combination therapy with ...

Further information
2013 CORPORATE
03.12.2013

News: Biotest AG: Biotest-EpiVax Collaborative Research Targets New, Non-Immunogenic Treatment for Hemophilia A

Biotest-EpiVax Collaborative Research Targets New, Non-Immunogenic Treatment for Hemophilia A Dreieich/ Germany, Rhode Island/ USA, 3 December 2013. Biotest AG, Dreieich, Germany and EpiVax, Inc., Providence, Rhode Island, USA are pleased to announce a new Collaborative Research Agreement. With this collaboration a novel, non-immunogenic Factor VIII (FVIII) should be developed. ...

Further information
2013 CORPORATE
20.11.2013

News: Biotest AG: Biotest Pharmaceuticals Honoured with the 2013 Greater Miami Chamber of Commerce International Business Leadership Award for 'Business Expansion'

Biotest Pharmaceuticals Honoured with the 2013 Greater Miami Chamber of Commerce International Business Leadership Award for 'Business Expansion' Boca Raton, FL, US/ Dreieich, Germany, November 20, 2013 - Biotest Pharmaceuticals Corporation (BPC), a wholly owned US subsidiary of Biotest AG, (Dreieich Germany), announced yesterday that it has been awarded the 2013 ...

Further information
2013 CORPORATE
12.11.2013

News: Biotest AG: Biotest increases guidance significanty

Biotest increases guidance significanty - Increase of earnings before tax (EBT) by 41.2% - EBIT increase by 21.6% - Successful placement of a privately placed promissory note (Schuldschein) of EUR 210 million equivalent in the capital market Dreieich, November 12, 2013. The Biotest Group increased sales by 13.1 % in the first nine months of 2013 compared to the ...

Further information
2013 CORPORATE
12.11.2013

Adhoc: Biotest AG: Managing Board increases guidance 2013

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Managing Board increases guidance 2013 Dreieich, 12 November 2013. The Managing Board of Biotest AG significantly raised the company's forecast for profit before interest and tax (EBIT) in the current year. The Management now expects a sales increase of 10% - 15% and an EBIT increase of 15% - 20%. Until now ...

Further information
2013 ADHOC
28.10.2013

News: Biotest AG: Biotest presents the results of a Phase II study of tregalizumab (BT-061) at the American College of Rheumatology (ACR) Annual Meeting in San Diego

/ Biotest presents the results of a Phase II study of tregalizumab (BT-061) at the American College of Rheumatology (ACR) Annual Meeting in San Diego - Good Efficacy and safety data of previous trials confirmed - The study protocol of a new Phase IIb study (TREAT 2b) has been approved in several countries Dreieich/ Germany, October 28, 2013. Biotest AG today announced ...

Further information
2013 CORPORATE
24.10.2013

News: Biotest AG: Biotest AG successfully placed a Schuldschein of EUR 210 m.

Biotest AG successfully placed a Schuldschein of EUR 210 m. - Three times oversubscribed due to the significant investor demand - Further milestone for the financing of the company growth strategy achieved Dreieich, October 24, 2013 - Biotest successfully placed a Schuldschein of approx. EUR 210 m. Commerzbank Aktiengesellschaft and Landesbank Hessen-Thüringen ...

Further information
2013 CORPORATE
15.10.2013

News: Biotest AG: Biotest supports the 'Project Recovery' in turning unused blood products from Canadian blood donations into hemophilia medicine for developing countries

Biotest supports the 'Project Recovery' in turning unused blood products from Canadian blood donations into hemophilia medicine for developing countries - This project will enable the WFH (World Federation of Hemophila) to improve its Humanitarian Aid Program - Biotest to manufacture Haemoctin(R) in Dreieich, Germany Dreieich/ Montreal, October 15, 2013 - The World Federation of ...

Further information
2013 CORPORATE
11.10.2013

News: Biotest AG: Biotest AG opens three further plasmapheresis centers in Hungary and the USA

Biotest AG opens three further plasmapheresis centers in Hungary and the USA - Inauguration opening of new collection center in Budapest marks doubling of capacities in Hungary - Two new centers already opened in USA in 2013, with two additional centers to follow in Florida Dreieich, October 11, 2013 - Today, Biotest is celebrating the opening of its second ...

Further information
2013 CORPORATE
13.08.2013

News: Biotest AG: Biotest increases earnings after tax by 55%

Biotest increases earnings after tax by 55% - New sales record in second quarter 2013 - Capital increase very successfully completed - Confirmation of Guidance of sales and EBIT growth of 10 - 15% in 2013 Dreieich, 13 August 2013. The Biotest Group achieved record sales in the first six months of 2013 and is still on its projected growth path. In the reporting ...

Further information
2013 CORPORATE
05.08.2013

News: Biotest AG: First patient treated with CivacirTM after Hepatitis C induced liver transplantation in Biotest's Phase III clinical trial

First patient treated with CivacirTM after Hepatitis C induced liver transplantation in Biotest's Phase III clinical trial - 50% of liver transplantations are due to Hepatitis C infection - High unmet medical need: Prevention of Hepatitis C virus recurrence in liver transplant - CivacirTM has an orphan drug designation in both the US and the EU Dreieich, 05 ...

Further information
2013 CORPORATE
26.06.2013

News: Biotest AG: Biotest AG successfully completes capital increase 2013: New shares were oversubscribed, Issuing volume amounts to EUR 76 million

Biotest AG successfully completes capital increase 2013: New shares were oversubscribed, Issuing volume amounts to EUR 76 million Dreieich, June 26, 2013 - During this year's annual shareholders meeting of Biotest AG, chief executive officer Professor Dr. Gregor Schulz announced a capital increase to finance the company's expansion strategy. Today Biotest announces the ...

Further information
2013 CORPORATE
10.06.2013

Adhoc: Biotest AG: Biotest AG has resolved to utilise its authorised capital with subscription rights for existing shareholders

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest AG has resolved to utilise its authorised capital with subscription rights for existing shareholders Dreieich, 10 June 2013 - The management board and supervisory board of Biotest AG have resolved today to increase the share capital of Biotest AG (the 'Company') from EUR 30,025,152.00 by up to EUR ...

Further information
2013 ADHOC
10.06.2013

Adhoc: Biotest AG: Biotest AG sets the subscription price and the offer price for the new preferred shares at EUR 52.00 per preferred share

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest AG sets the subscription price and the offer price for the new preferred shares at EUR 52.00 per preferred share Dreieich, 10 June 2013 - The management board of Biotest AG decided today, in consultation with equinet Bank AG, on the further parameters for the capital increase against cash ...

Further information
2013 ADHOC
08.05.2013

Adhoc: Biotest AG: Biotest AG plans a capital increase and rights issue

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest AG plans a capital increase and rights issue Dreieich, 8 May 2013 - Today, Management Board and Supervisory Board of Biotest AG have resolved on a planned capital increase from authorised capital against cash contributions. Biotest AG plans to increase its share capital from EUR 30,025,152.00 by ...

Further information
2013 ADHOC
08.05.2013

News: Biotest AG: Biotest AG: Annual general meeting approves increase of dividend

Biotest AG: Annual general meeting approves increase of dividend - Distribution of EUR 0.50 per ordinary share and EUR 0.56 per preference share Dreieich / Frankfurt a. M., 8 May 2013. At the annual general meeting (AGM) held on 8 May 2013 in Frankfurt am Main shareholders of Biotest AG approved payment of an increased dividend. With 82,4 percent of the ordinary ...

Further information
2013 CORPORATE
08.05.2013

News: Biotest AG: Biotest Group reports increase of EBIT

Biotest Group reports increase of EBIT - EBIT up 13.5% at EUR 11.8 million - Sales increased to EUR 118.7 million - Management Board confirms guidance Dreieich, 8 May 2013. In the first three months of financial year 2013 the Biotest Group was able to significantly increase sales again and achieve a new quarterly sales record. In the reporting period the Group ...

Further information
2013 CORPORATE
25.03.2013

News: Biotest AG: Biotest increases Profit before Tax by 28%

Biotest increases Profit before Tax by 28% - Profit after tax of the Biotest Group (Continuing Operations) at EUR23.1 million represents an increase of 23.5% vs. the previous year - Revenue increase by 4.3% Dreieich, 25 March 2013. In 2012 the Biotest Group has increased the profit after tax of the Continuing Operations by 23.5% compared to the previous year, the ...

Further information
2013 CORPORATE
21.03.2013

News: Biotest AG: Biotest decides to move into biggest Phase IIb trial in company history

Biotest decides to move into biggest Phase IIb trial in company history Dreieich, 21 March 2013. Biotest announced today that Biotest intends to start an additional Phase IIb trial with up to 350 patients with Tregalizumab (BT-061), a monoclonal antibody in development for the treatment of Rheumatoid Arthritis. Tregalizumab, which activates regulatory T-cells of the patient's ...

Further information
2013 CORPORATE
21.02.2013

Adhoc: Biotest AG: Biotest increases earnings before taxes by 28%

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest increases earnings before taxes by 28% Dreieich, 21. February 2013. According to preliminary and unaudited figures, the Biotest Group recorded Earnings before taxes (EBT) of EUR 36.5 million for its Continuing Operations (previous year result EUR 28.6 million). The main factors for this profit ...

Further information
2013 ADHOC
04.02.2013

News: Biotest AG: Biotest announces launch of BIVIGAM(TM)in the United States

Biotest announces launch of BIVIGAM(TM)in the United States Dreieich, February 4, 2013 - Biotest announces the launch of BIVIGAM(TM) in the US market. BIVIGAM(TM) is a human intravenous immune globulin 10% liquid, which will be distributed by Biotest Pharmaceuticals Corporation (BPC) a wholly owned U.S. subsidiary of Biotest AG. The product is now available on a regular basis ...

Further information
2013 CORPORATE
22.01.2013

Adhoc: Biotest AG: Increase in Earnings after Tex for Fiscal Year 2012

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Dreieich, 22 January 2013. Biotest AG announces that earnings after tax for the year 2012 will increase by approx. EUR 10 million. (This additional income will be reported in earnings after tax from Discontinued Operation.) This income results from the sale of the former segment Microbiological Monitoring. At ...

Further information
2013 ADHOC
21.01.2013

News: Biotest AG: Biotest AG with new sales and distribution activities in Russia and Greece

Biotest AG with new sales and distribution activities in Russia and Greece - Biotest AG concentrates its sales activities on Russian market through cooperation with Merz Pharma GmbH & Co. KGaA - Transfer of Distribution Rights in Greece from Biotest AG to Vianex s.a. Dreieich, January 21, 2013. Biotest is aiming to further expand its already strong position on ...

Further information
2013 CORPORATE
16.01.2013

News: Biotest AG: Biotest Announces Strategic Long-Term Manufacturing, Supply and License Agreement

Biotest Announces Strategic Long-Term Manufacturing, Supply and License Agreement - Manufacturing & Supply agreement - License agreement for ADMA's Respiratory Syncytial Virus IGIV product candidate for EU and selected countries Dreieich/ Boca Raton, January 16, 2013 - Biotest announces, that Biotest Pharmaceuticals Corp. (BPC), a wholly owned U.S. subsidiary of ...

Further information
2013 CORPORATE
09.01.2013

News: Biotest AG: Biotest AG's Supervisory Board extends the term of CEO Prof. Schulz and appoints Dr. Floß to the Board of Management

Biotest AG's Supervisory Board extends the term of CEO Prof. Schulz and appoints Dr. Floß to the Board of Management Dreieich, January 9, 2013: Today the Supervisory Board of Biotest AG extended the term of CEO Prof. Dr. Gregor Schulz till December 31, 2014. Prof. Schulz manages the Biotest Group as Chairman of the Board of Management since ten years. In this period revenues ...

Further information
2013 CORPORATE
20.12.2012

News: Biotest AG: FDA Approves Biotest's BIVIGAM(TM), an Intravenous Immune Globulin (Human), 10% liquid

FDA Approves Biotest's BIVIGAM(TM), an Intravenous Immune Globulin (Human), 10% liquid Dreieich, Germany and Boca Raton, Florida December 20 2012: Biotest AG announced today that Biotest Pharmaceuticals Corporation received approval for Bivigam(TM) for the treatment of patients with Primary Humoral Immunodeficiency (PI) from the U.S. Food and Drug Administration ...

Further information
2012 CORPORATE
20.12.2012

Adhoc: Biotest AG: FDA Approves Bivigam TM

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Dreieich, Germany and Boca Raton, Florida December 20, 2012: Biotest AG announced today that Biotest Pharmaceuticals Corporation, a wholly owned subsidiary of the listed Biotest AG, received approval for BIVIGAM(TM) for the treatment of patients with Primary Humoral Immunodeficiency (PI) from the U.S. Food ...

Further information
2012 ADHOC
13.12.2012

News: Biotest AG: Biotest with new management team for research and regulatory affairs

Biotest with new management team for research and regulatory affairs - Dr. Jörg Schüttrumpf takes over responsibility for pre-clinical research and development as new Head of Global Research - Experienced physician and pharmaceutical manager Prof. Dr. Markus Rothenburger is assuming the position as Head of Medical/ Regulatory Affairs at the beginning of next ...

Further information
2012 CORPORATE
11.12.2012

News: Biotest AG: Biotest AG signs strategically significant agreement to market human albumin in China

Biotest AG signs strategically significant agreement to market human albumin in China - Access to fast growing, high-price Chinese albumin market - Revenue of EUR 20 to EUR 30 million expected in medium term - Strong sales and distribution partner Wanbang Biopharma, a Fosun Pharma Group company, as guarantee for success Dreieich, December 11, 2012. By signing ...

Further information
2012 CORPORATE
06.12.2012

News: Biotest AG: Biotest starts clinical development programme of human fibrinogen concentrate to treat serious, life-threatening bleeding

Biotest starts clinical development programme of human fibrinogen concentrate to treat serious, life-threatening bleeding - Approval of study protocol to conduct a phase I/II clinical trial - Treatment of first patient with congenital fibrinogen deficiency is expected shortly Dreieich, 6. December 2012. After approval of the study protocol Biotest will start ...

Further information
2012 CORPORATE
13.11.2012

News: Biotest AG: Biotest increases EBT by 26%

Biotest increases EBT by 26% - EBIT increase by 9.0% - BivigamTM - 'Complete Response Letter' sent to FDA - Long term Agreement closed with ViroPharma, USA Dreieich, 13. November 2012. During the first nine months of 2012, the Biotest Group was able to increase its revenue by 4.2% compared with sales from Continuing Operations in the same period of 2011. Thus, the ...

Further information
2012 CORPORATE
24.10.2012

News: Biotest AG: Biotest AG expands existing product portfolio with the marketing authorisation of Intratect 100 g/l (10%)

Biotest AG expands existing product portfolio with the marketing authorisation of Intratect 100 g/l (10%) - Marketing authorisation of Intratect 100 g/l (10%) under the European Decentralised Procedure - Marketing of the new product possible in 18 other European countries in addition to Germany - Market introduction in Germany expected from January ...

Further information
2012 CORPORATE
13.08.2012

News: Biotest AG: Biotest Group with double digit EBIT growth

Biotest Group with double digit EBIT growth - Sales increase to EUR 220.2 mio. - EBIT increase by 14.5% to EUR 22.9 EUR mio. - Management confirms guidance 2012 Dreieich, 13 August 2012. The Biotest Group was once again able to increase revenues in the first half of 2012 compared with sales from continuing operations in the same period of 2011. Revenues in the first ...

Further information
2012 CORPORATE
07.08.2012

News: Biotest AG: Clinical Data on Efficacy and Safety of Bivigam(TM) accepted by FDA. Sales and profit guidance confirmed despite delays in US registration.

Clinical Data on Efficacy and Safety of Bivigam(TM) accepted by FDA. Sales and profit guidance confirmed despite delays in US registration. Dreieich, Germany, 7 August 2012: In an official statement by the United States Food and Drug Administration, FDA, received on August 6, 2012 no questions were raised on the clinical efficacy and safety of the newly developed ...

Further information
2012 CORPORATE
16.07.2012

News: Biotest AG: Biotest AG starts combination therapy study with BT-062 in multiple myeloma

Biotest AG starts combination therapy study with BT-062 in multiple myeloma - Antibody-drug conjugate BT-062 continues to show good tolerability in monotherapy - First patient treated in phase I/IIa combination therapy study (no. 983) in multiple myeloma - Funding for further activities in solid tumours approved by excellence cluster CI3 Rhine-Main ...

Further information
2012 CORPORATE
10.05.2012

News: Biotest AG: Annual general meeting approves dividend

Biotest AG: Annual general meeting approves dividend - Distribution of EUR 0.44 per ordinary share and EUR 0.50 per preference share - Dr. Alessandro Banchi elected as new Supervisory Board Chairman Dreieich / Frankfurt a. M., 10 May 2012. At the annual general meeting (AGM) held on 10 May 2012 in Frankfurt am Main shareholders of Biotest AG approved payment of a ...

Further information
2012 CORPORATE
10.05.2012

News: Biotest AG: Biotest Group reports substantially higher EBIT

Biotest Group reports substantially higher EBIT - EBIT up 14.3% at EUR 10.4 million - Sales increased to EUR 107.7 million - Management Board confirms forecast Dreieich, 10 May 2012. The Biotest Group has increased its earnings before interest and taxes (EBIT) in the first three months of the 2012 financial year by a substantial 14.3%. The company generated earnings ...

Further information
2012 CORPORATE
08.05.2012

Adhoc: Biotest AG: Preliminary investigation by public prosecution - Company rejects suspicions

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Preliminary investigation by public prosecution - Company rejects suspicions Dreieich, May 8, 2012 - The Frankfurt public prosecutor today initiated a preliminary investigation at Biotest AG, Dreieich. This is based on an anonymous allegation against several persons which accuses also employees of Biotest ...

Further information
2012 ADHOC
23.04.2012

News: Biotest consolidates its outstanding position in the hepatitis B hyperimmunoglobulin market with the marketing authorisation of Fovepta and with the initial sales of Hepatect(R) in Brazil

Biotest consolidates its outstanding position in the hepatitis B hyperimmunoglobulin market with the marketing authorisation of Fovepta and with the initial sales of Hepatect(R) in Brazil - Marketing authorisation of Fovepta(R) in Germany - Initial sales of Hepatect(R) in Brazil - Continuation of the clinical development of Civacir(TM) planned for the second half of ...

Further information
2012 CORPORATE
11.04.2012

News: Biotest AG: Biotest announces clinical trial data for its new investigational Intravenous Immunoglobulin (IVIG) product for the US market

Biotest announces clinical trial data for its new investigational Intravenous Immunoglobulin (IVIG) product for the US market Dreieich, 11 April 2012. Biotest AG announces the publication of its US subsidiary Biotest Pharmaceuticals Corporation (BPC), Boca Raton, Florida, USA of Wasserman et al.,: 'Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous ...

Further information
2012 CORPORATE
22.03.2012

News: Biotest AG: Biotest reached an all-time high Profit after Tax

Biotest reached an all-time high Profit after Tax - Profit after tax of the Biotest Group (Continuing Operations and Discontinued Operation) at EUR48.1 million represents an increase of 21.8% vs. the previous year - Profit after tax contribution of EUR26.4 million from sale of Microbiological Monitoring - Revenue increase by 2.3% Dreieich, 22 March 2012. ...

Further information
2012 CORPORATE
22.03.2012

News: Biotest AG: BT-062 demonstrates rapid and complete tumor eradication in preclinical studies

BT-062 demonstrates rapid and complete tumor eradication in preclinical studies - Pronounced anti-tumor activity against aggressive solid tumors, e.g. human breast, pancreas, bladder and lung cancers in preclinical studies - Data show efficacy in indications with a particularly high medical need - Project proposal selected for application to center of ...

Further information
2012 CORPORATE
15.03.2012

PVR: Biotest AG: Correction of a Publication according to § 26 paragraph. 1 WpHG from February 22, 2012 with the objective of Europe-wide distribution

Notification of voting rights pursuant to sec. 41 para. 4d WpHG We received the following notification pursuant to sec. 41 para. 4d WpHG on February 22, 2012: 1. Listed company: Biotest AG Landsteinerstraße 5, 63303 Dreieich, Deutschland 2. Notifier: Mr Martin Dr. Schleussner, Deutschland 3. Total amount of voting rights held on February 1st, 2012: 50,27% (equals 3315508 voting ...

Further information
2012 PVR
15.03.2012

PVR: Biotest AG: Correction of a Publication according to § 26 paragraph. 1 WpHG from February 22, 2012 with the objective of Europe-wide distribution

Notification of voting rights pursuant to sec. 41 para. 4d WpHG We received the following notification pursuant to sec. 41 para. 4d WpHG on February 22, 2012: 1. Listed company: Biotest AG Landsteinerstraße 5, 63303 Dreieich, Deutschland 2. Notifier: Mr Hans Dr. Schleussner, Deutschland 3. Total amount of voting rights held on February 1st, 2012: 50,27% (equals 3315508 voting ...

Further information
2012 PVR
15.03.2012

PVR: Biotest AG: Correction of the Publication according to § 26 paragraph. 1 WpHG from February 22, 2012 with the objective of Europe-wide distribution

Notification of voting rights pursuant to sec. 41 para. 4d WpHG We received the following notification pursuant to sec. 41 para. 4d WpHG on February 22, 2012: 1. Listed company: Biotest AG Landsteinerstraße 5, 63303 Dreieich, Deutschland 2. Notifier: Ms Renate Scheussner, Deutschland 3. Total amount of voting rights held on February 1st, 2012: 50,27% (equals 3315508 voting ...

Further information
2012 PVR
22.02.2012

PVR: Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of voting rights pursuant to sec. 41 para. 4d WpHG We received the following notification pursuant to sec. 41 para. 4d WpHG on February 22, 2012: 1. Listed company: Biotest AG Landsteinerstraße 5, 63303 Dreieich, Deutschland 2. Notifier: Ms Renate Schleussner, Deutschland 3. Total amount of voting rights held on February 1st, 2012: 50,27% (equals 3315508 voting ...

Further information
2012 PVR
22.02.2012

PVR: Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of voting rights pursuant to sec. 41 para. 4d WpHG We received the following notification pursuant to sec. 41 para. 4d WpHG on February 22, 2012: 1. Listed company: Biotest AG Landsteinerstraße 5, 63303 Dreieich, Deutschland 2. Notifier: Mr Martin Dr. Schleussner, Deutschland 3. Total amount of voting rights held on February 1st, 2012: 50,27% (equals 3315508 voting ...

Further information
2012 PVR
22.02.2012

PVR: Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of voting rights pursuant to sec. 41 para. 4d WpHG We received the following notification pursuant to sec. 41 para. 4d WpHG on February 22, 2012: 1. Listed company: Biotest AG Landsteinerstraße 5, 63303 Dreieich, Deutschland 2. Notifier: Mr Hans Dr. Schleussner, Deutschland 3. Total amount of voting rights held on February 1st, 2012: 50,27% (equals 3315508 voting ...

Further information
2012 PVR
20.02.2012

Adhoc: Biotest AG: Slight increase in sales of 2.3% despite difficult market environment

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest: Slight increase in sales of 2.3% despite difficult market environment Dreieich, 20 February 2012. According to preliminary and unaudited figures, the Biotest Group (Plasma Proteins and Biotherapeutics) recorded sales of EUR 422.0 million in the financial year 2011, an increase of 2.3% compared to ...

Further information
2012 ADHOC
09.02.2012

AFR: Biotest AG: Announcement according to Articles 37v, 37w, 37x et seqq. of the WpHG [the German Securities Act] with the objective of Europe-wide distribution

Biotest AG hereby announces that the following financial reports shall be disclosed : Report: Annual financial report Date of disclosure / German: March 22, 2012 German: http://www.equitystory.com/download/Companies/biotest/Annual%20Reports/Biotest_Einzelabschluss2011.pdf Report: Annual financial report of the group Date of disclosure / German: March 22, 2012 Date of disclosure / English: ...

Further information
2012 AFR
12.12.2011

News: Biotest AG: Clinical development of BT-062 in multiple myeloma expands into combination therapy

Clinical development of BT-062 in multiple myeloma expands into combination therapy  Efficacy and tolerability data from monotherapy studies 969 and 975 presented at 53rd annual conference of the American Society of Hematology  Clinical benefit already seen in more than 50 % of patients receiving repeat single-dose regimen  Good tolerability confirmed with multi-dose regimen at ...

Further information
2011 CORPORATE
24.11.2011

News: Biotest AG: Tregalizumab (BT-061) shows efficacy in Chronic Plaque Psoriasis

Tregalizumab (BT-061) shows efficacy in Chronic Plaque Psoriasis  Final results of the first repeated dose phase II trial in Chronic Plaque Psoriasis show efficacy in the higher subcutaneous dose groups  Good tolerability confirmed  Further development in Psoriasis will be based on results of larger clinical trials in Rheumatoid Arthritis Dreieich, 24 November 2011. In its ...

Further information
2011 CORPORATE
10.11.2011

News: Biotest AG: Biotest: Significant Increase in Profit after Tax

Biotest: Significant Increase in Profit after Tax - Increase of Profit after tax by 31.1% (Continuing and Discontinued Operations) - Profit after tax contribution of EUR 22 million from sale of Microbiological Monitoring - Increase of Profit after tax by 14.1% (Continuing Operations) - Revenue increase by 1.9% Dreieich, 10 November 2011. In the first nine months of 2011 the ...

Further information
2011 CORPORATE
11.08.2011

News: Biotest AG: First time Revenue and EBIT contribution by Biotherapeutics Segment; continuing difficult Plasma Protein Product Environment

First time Revenue and EBIT contribution by Biotherapeutics Segment; continuing difficult Plasma Protein Product Environment - Sales increased by 4,9 % in first half of 2011 in continuing operations - Earnings situation burdened by market environment and unabsorbed costs in the US - Global Development and Cooperation contract with Abbott for BT 061 Dreieich, 11 August 2011. The Biotest ...

Further information
2011 CORPORATE
01.08.2011

News: Biotest AG: Sale of Microbiological Monitoring business to Merck KGaA completed

Sale of Microbiological Monitoring business to Merck KGaA completed - Transaction has been successfully closed today after clearance of merger control authorities was given - Biotest focusses now on Plasmaproteins and Biotherapeutics Dreieich, 1st August, 2011. All relevant merger control authorities approved the sale of Biotest's AG woldwide activities of its Microbiological Monitoring ...

Further information
2011 CORPORATE
22.06.2011

News: Biotest AG: Pentaglobin(R) shows high binding capacity against the current EHEC strain and its Shiga-like toxin 2

Pentaglobin(R) shows high binding capacity against the current EHEC strain and its Shiga-like toxin 2 - First analysis show positive results - Pentaglobin(R) contains antibodies with high binding capacity against surface antigens of the current EHEC strain HUSEC041 Dreieich, 22. June 2011. New preclinical data might give new hopes for EHEC patients and their physicians. The human ...

Further information
2011 CORPORATE
21.06.2011

Adhoc: Biotest AG: Agreement with Abbott

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Dreieich, June 21, 2011 - Abbott and Biotest AG today announced a global agreement to develop and commercialize BT-061, a novel anti-CD4 antibody for the treatment of rheumatoid arthritis (RA) and psoriasis. BT-061 is currently in Phase II clinical trials for RA and psoriasis, with preclinical studies underway ...

Further information
2011 ADHOC
21.06.2011

News: Biotest AG: Abbott and Biotest Announce Global Agreement to Development and Commercialize Novel Antibody for Autoimmune Diseases

Abbott and Biotest Announce Global Agreement to Development and Commercialize Novel Antibody for Autoimmune Diseases BT-061 in clinical development for the treatment of RA and psoriasis ABBOTT PARK, Ill. and DREIEICH, Germany, June 21, 2011 - Abbott and Biotest AG today announced a global agreement to develop and commercialize BT-061, a novel anti-CD4 antibody for the treatment of rheumatoid ...

Further information
2011 CORPORATE
12.05.2011

News: Biotest AG: Biotest AG: Annual General Meeting approves dividend increase

Biotest AG: Annual General Meeting approves dividend increase - Approved dividend of EUR 0.38 per ordinary share and EUR 0.44 per preference share - Total distribution payment up to more than EUR 4.7 million Dreieich/ Frankfurt am Main, May 12, 2011 - The Annual General Meeting of Biotest AG with 84.1 % of shareholder present, approved a dividend of EUR 0.38 per ordinary share for 2010 ...

Further information
2011 CORPORATE
10.05.2011

News: Biotest AG: Sales increase in the first quarter

Sales increase in the first quarter  Sales in Continuing Operations grow by 3.6% compared to the same period in the previous year to EUR106.5 million; EBIT below previous-year level  Company continues to focus on and internationalise its core business  Progress made in major development projects Dreieich, 10 May 2011. The sales of the Biotest Group in the first quarter of 2011 grew to ...

Further information
2011 CORPORATE
28.04.2011

Adhoc: Biotest AG: Ad hoc ANNOUNCEMENT

Ad hoc ANNOUNCEMENT Announcement in accordance with Section 15 (1) of the German Securities Trading Act (WpHG) Dreieich, 28 April 2011. The Board of Management of Biotest AG has adjusted its 2011 earnings targets for the Continuing Operations of the Biotest Group but affirmed its sales goal. This is due to events at the subsidiary Biotest Pharmaceuticals Corporation (BPC), Boca Raton, USA, ...

Further information
2011 ADHOC
22.03.2011

News: Biotest AG: Sales increase despite difficult market environment

Sales increase despite difficult market environment  Sales increased by 5.7% to EUR 412.5 million, EBIT decreased by 24.9% due to a difficult market environment for plasma proteins  Biotest signs contract to sell its Microbiological Monitoring business to Merck KGaA  Further R&D progress with plasma proteins and biotherapeutics Dreieich, March,22, 2011. In 2010, the Biotest Group ...

Further information
2011 CORPORATE
22.03.2011

Adhoc: Biotest AG: Ad-hoc RELEASE Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG)

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Dreieich, March 22, 2011. Biotest AG has signed tonight a contract today to sell its woldwide activities of its Microbiological Monitoring business, consisting of the product portfolio of HYCON (hygiene monitoring) and the product portfolio of heipha Dr. Müller GmbH (microbiological culture media and ...

Further information
2011 ADHOC
22.03.2011

News: Biotest AG: Biotest: Monoclonal antibody BT-061 in combination with methotrexate demonstrates good efficacy in Rheumatoid Arthritis

Biotest: Monoclonal antibody BT-061 in combination with methotrexate demonstrates good efficacy in Rheumatoid Arthritis  A further phase II trial of BT-061 in Rheumatoid Arthritis concluded  Preliminary analysis shows good clinical efficacy also in combination with the disease-modifying drug methotrexate  Effective dose range confirmed after subcutaneous administration of BT-061  ...

Further information
2011 CORPORATE
25.02.2011

AFR: Biotest AG: Announcement according to Articles 37v, 37w, 37x et seqq. of the WpHG [the German Securities Act] with the objective of Europe-wide distribution

Biotest AG hereby announces that the following financial reports shall be disclosed : Report: Annual financial report Date of disclosure / German: March 22, 2011 German: http://irpages.equitystory.com/download/Companies/biotest/Annual%20Reports/Biotest_Einzelabschluss2010.pdf Report: Annual financial report of the group Date of disclosure / German: March 22, 2011 Date of disclosure / ...

Further information
2011 AFR
15.02.2011

Adhoc: Biotest AG: Increase in sales of more than 5%

Biotest: Increase in sales of more than 5% Dreieich, 15 February 2011. According to preliminary and unaudited figures, the Biotest Group (Plasma Proteins and Microbiological Monitoring) recorded sales of EUR 461.2 million in the financial year 2010, an increase of 5.2% compared to the previous year (EUR 438.6 million). Earnings before interest and tax (EBIT) of the Group (Plasma ...

Further information
2011 ADHOC
27.01.2011

News: Biotest AG: Interim analysis of the Cytotect(R) Phase III trial in congenital cytomegalovirus (CMV) infection shows clear indication of efficacy

Interim analysis of the Cytotect(R) Phase III trial in congenital cytomegalovirus (CMV) infection shows clear indication of efficacy  Positive results justify continuation of the Phase III trial  7,000 pregnant women have been included in the trial so far Dreieich, 27 January 2011, Biotest has conducted an interim analysis of a Phase III clinical trial with the anti-cytomegalovirus ...

Further information
2011 CORPORATE
19.01.2011

News: Biotest AG: Biotest erwirbt Vertriebsgesellschaft in Brasilien

Biotest acquires Brazilian distributor - Acquisition of Biotest distributor 'Marcos Pedrilson Produtos Hospitalares Ltda.' in Rio de Janeiro - Immediate sales in 2011 - Strong sales and earnings growth expected in the medium term based on new market approvals of immunoglobulins Dreieich, 19 January 2011. Biotest AG, Dreieich, has acquired all interests in 'Marcos Pedrilson Produtos ...

Further information
2011 CORPORATE
06.12.2010

News: Biotest AG: Clinical and pre-clinical data emphasise the potential of

Clinical and pre-clinical data emphasise the potential of BT-062 in multiple myeloma  Phase I clinical trial: BT-062 leads to clinical benefit in more than 50 % of patients with continued good tolerability  Pre-clinical data show the potential of BT-062 in combination therapy with approved drugs  Presentation of the data at the 52nd annual conference of the American Society of ...

Further information
2010 CORPORATE
17.11.2010

News: Biotest AG: Biotest: Pre-clinical studies demonstrate high efficacy of BT-062 in solid tumours

Biotest: Pre-clinical studies demonstrate high efficacy of BT-062 in solid tumours  Immunoconjugate induces complete remission of human solid tumours in mouse models  High anti-tumour activity against aggressive human breast, pancreas, bladder and lung carcinoma  Data show efficacy in indications with a particularly great medical need Dreieich, Germany, 17 November 2010. Today ...

Further information
2010 CORPORATE
08.11.2010

News: Biotest AG: Biotest experiences sales growth

Biotest experiences sales growth  Sales after nine months 3.5% above the previous year  Performance continues to be affected by the difficult market environment  Board of Management confirms projections for the year as a whole Dreieich, 8 November 2010. In the first nine months of financial year 2010, the Biotest Group recorded sales of EUR342.3 million in its Continuing Operations, ...

Further information
2010 CORPORATE
03.11.2010

News: Biotest AG: Biotest submits BivigamTM dossier for regulatory approval to US Food and Drug Administration

Biotest submits BivigamTM dossier for regulatory approval to US Food and Drug Administration  Important step to expand US market position  Annual sales potential of around USD 100 Mio.  Biotest expects approval for end of 2011 Dreieich, 3 November 2010. Biotest Pharmaceutiocals Corp., Boca Raton/ USA has submitted today the dossier for regulatory approval of the ...

Further information
2010 CORPORATE
21.10.2010

News: Biotest AG: Monoclonal antibody BT-061 shows potential in the indication multiple sclerosis

Monoclonal antibody BT-061 shows potential in the indication multiple sclerosis - Biotest generates positive pre-clinical data in the indication multiple sclerosis - Further development in this indication supported by the German Federal Ministry of Education and Research in the framework of the 'Neu² Konsortium' Dreieich, 21. October 2010. Biotest has obtained positive ...

Further information
2010 CORPORATE
12.08.2010

News: Biotest AG: Positive perspective despite difficult environment

Positive perspective despite difficult environment - Final results for first half of 2010: sales increased by 4 % - Earnings situation burdened by market environment - Important progress in R&D projects achieved Dreieich, 12 August 2010. The Biotest Group presented its half-year report as of 30 June 2010 today. The Group recorded a slight revenue increase of 4% in the first half of 2010, ...

Further information
2010 CORPORATE
11.08.2010

News: Biotest AG: Development of BT-062 makes further progress with start of a new clinical trial

Biotest: Development of BT-062 makes further progress with start of a new clinical trial - Phase I clinical study completes patient recruitment - Encouraging results concerning efficacy and tolerability - Phase I/IIa clinical trial in multiple myeloma has started Dreieich, Germany, 11. August 2010. Biotest AG is pursuing an innovative therapeutic strategy to treat multiple myeloma using the ...

Further information
2010 CORPORATE
10.08.2010

News: Biotest AG: Immunomodulatory antibody BT-061 shows competitive efficacy in the indication Rheumatoid Arthritis

Immunomodulatory antibody BT-061 shows competitive efficacy in the indication Rheumatoid Arthritis - Phase IIa monotherapy trial completed - Competitive clinical efficacy already after a short treatment period - Good safety and tolerability profile confirmed Dreieich, Germany, 10. August 2010. Biotest AG is pleased to announce final data from a phase IIa clinical trial with its ...

Further information
2010 CORPORATE
10.08.2010

News: Biotest AG: BT-061 patent protection significantly expanded

Biotest: BT-061 patent protection significantly expanded - Compound patent granted in most important pharma markets - Valuable asset for future partnerships Dreieich, Germany, 10. August 2010. Biotest AG, a provider of pharmaceutical and biotherapeutic drugs for immunological and haematological diseases, announced today that a key patent for its unique monoclonal antibody drug candidate ...

Further information
2010 CORPORATE
14.07.2010

News: Biotest AG: Biotest increases sales despite greater financial pressure

Biotest increases sales despite greater financial pressure - In the first half of 2010, sales up 4.0% on the previous year at EUR 227.1 million - Market environment and government savings package impact earnings - Board of Management scales down expectations for the full year 2010 Dreieich, Germany, 14 July 2010. Today, the Biotest Group issued an ad hoc announcement containing ...

Further information
2010 CORPORATE
14.07.2010

Adhoc: Biotest AG: Preliminary Results

Dreieich, Germany, 14 July 2010. According to preliminary figures, the Biotest Group recorded a slight revenue increase of 4% in the first half of 2010, taking sales to EUR227.1 million (first half of 2009: EUR218.4 million). The Group generated earnings before interest and taxes (EBIT) of EUR23.7 million (previous year: EUR31.2 million. Earnings fell short of the Company's expectations, ...

Further information
2010 ADHOC
11.05.2010

News: Biotest AG: Biotest shows sales growth in first quarter 2010 despite a difficult environment

Biotest shows sales growth in first quarter 2010 despite a difficult environment - Q1 2010: Revenue Growth of 5.2 % and EBIT decrease due to high R&D expenses as well as price declines - Earnings after tax nearly tripled to EUR 22.6 million due to extraordinary income from the sale of Medical Diagnostics - Outlook 2010 confirmed Dreieich, May 11, 2010. Sales in the first quarter 2010 ...

Further information
2010 CORPORATE
06.05.2010

News: Biotest AG: Annual General Meeting 2010: Shareholders Approve Dividend of EUR 0.34 per Ordinary Share and EUR 0.40 per Preference Share

Annual General Meeting 2010: Shareholders Approve Dividend of EUR 0.34 per Ordinary Share and EUR 0.40 per Preference Share Dreieich/ Frankfurt am Main, May 6, 2010 - Shareholders of Biotest AG with 81.7% of shareholder present, approved a dividend of EUR 0.34 per ordinary share for 2009 and a dividend of EUR 0.40 per preference share at the company's Annual General Meeting held today in ...

Further information
2010 CORPORATE
06.05.2010

News: Biotest AG: Biotest has recorded sales growth in first quarter 2010 despite a difficult environment

Biotest has recorded sales growth in first quarter 2010 despite a difficult environment - Q1 2010: Revenue Growth of 5,2 % and EBIT decrease of 18,0 %; Earnings after Tax nearly tripled due to extraordinary income from the sale of Medical Diagnostics - Outlook 2010 confirmed Dreieich/ Frankfurt am Main, May 6, 2010 - In his speech at the Annual Shareholder's Meeting today, the Chairman ...

Further information
2010 CORPORATE
22.03.2010

AFR: Biotest AG: Announcement according to Articles 37v, 37w, 37x et seqq. of the WpHG [the German Securities Act] with the objective of Europe-wide distribution

This is an announcement of change. Biotest AG hereby announces that the following financial reports shall be disclosed: Report: Financial report of the group (half-year) Date of disclosure / German: August 12, 2010 Date of disclosure / English: August 12, 2010 German: http://www.equitystory.com/download/companies/biotest/Quarterly%20Reports/DE0005227235-Q2-2010-EQ-D-00.pdf English: ...

Further information
2010 AFR
19.03.2010

News: Biotest AG: 2009 brings additional growth

2009 brings additional growth - Sales up by 14.1% to EUR440.2 million, EBIT improved by 4.2% - Important progress made in R&E projects - Expanded position as specialist for immunological and haematological therapies Dreieich, 19 March 2010. The Biotest Group presented its definitive figures for the financial year 2009 today. The supplier of plasma proteins and diagnostic products for ...

Further information
2010 CORPORATE
17.03.2010

News: Biotest AG: Monoclonal antibody BT-061 shows efficacy in the indication psoriasis

Monoclonal antibody BT-061 shows efficacy in the indication psoriasis - Final results of Phase I/IIa trial in chronic plaque psoriasis show long- lasting therapeutic effect after a single administration in the relevant dose levels - Good safety confirmed by comprehensive testing - First patients treated in a new phase II trial with repeated dosing Dreieich, 17 March 2010. Biotest ...

Further information
2010 CORPORATE
16.02.2010

Adhoc: Biotest AG: Biotest significantly increases sales, EBIT above the high level of last year

Biotest significantly increases sales, EBIT above the high level of last year Dreieich, 16 February 2010. According to preliminary and unaudited figures, the Biotest Group (Continued Business) recorded sales of EUR 440.2 million in financial year 2009, an increase of 14.1% compared to the previous year (EUR 385.9 million). Earnings before interest and tax (EBIT) are in the range of EUR 61 ...

Further information
2010 ADHOC
04.02.2010

AFR: Biotest AG: Announcement according to Articles 37v, 37w, 37x et seqq. of the WpHG [the German Securities Act] with the objective of Europe-wide distribution

Biotest AG hereby announces that the following financial reports shall be disclosed: Report: Annual financial report Date of disclosure / German: March 19, 2010 German: http://irpages.equitystory.com/download/Companies/biotest/Annual%20Reports/Biotest_Einzelabschluss2009.pdf Report: Annual financial report of the group Date of disclosure / German: March 19, 2010 Date of disclosure / ...

Further information
2010 AFR
06.01.2010

News: Biotest AG: Sale of Medical Diagnostics business to Bio-Rad completed

Sale of Medical Diagnostics business to Bio-Rad completed - Transaction has been successfully closed today after clearance of merger control authorities was given - Biotest's Microbiology business in the US now with Biotest Microbiology Corp. Rockaway, NJ, USA Dreieich, 6. January 2010. All relevant European merger control authorities approved the sale of major parts of Biotest's Medical ...

Further information
2010 CORPORATE
07.12.2009

News: Biotest AG: Immunoconjugate BT-062 shows first data of clinical efficacy

Immunoconjugate BT-062 shows first data of clinical efficacy * Presentation of preliminary data of a multicenter Phase I Study in Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology * Further development in more intensive dosage programme Dreieich, 7 December 2009. At the Annual Meeting of the American Society of Hematology in New Orleans, Biotest presented ...

Further information
2009 CORPORATE
03.12.2009

News: Biotest AG: European Commission grants approval of Zutectra(R)

European Commission grants approval of Zutectra(R) * Worldwide the first ready-to-use Hepatitis B Immunoglobulin solution for subcutaneous administration * Marketing in Europe can start now Dreieich, 3. December 2009. The European Commission has granted marketing approval to Biotest for the hepatitis B immunoglobulin Zutectra(R) after the Committee for Medicinal Products for Human Use ...

Further information
2009 CORPORATE
05.11.2009

News: Biotest AG: Biotest increases sales and earnings

Biotest increases sales and earnings - Nine-month figures: sales increase by 12.0%, while EBIT grows by 3.0% - Forecast for the full year 2009 confirmed Dreieich, 5 November 2009. In the first nine months of 2009, the Biotest Group increased sales and earnings compared with the previous year's figures in the same period. Sales increased by 12.0% to EUR361.9 million (2008: EUR323.0 million). ...

Further information
2009 CORPORATE
23.10.2009

Adhoc: Biotest AG: Biotest agrees to sell its Medical Diagnostics business to Bio-Rad

Biotest agrees to sell its Medical Diagnostics business to Bio-Rad Dreieich, 23 October 2009. Biotest AG announced today that it has signed an agreement to sell major parts of its Medical Diagnostics segment to Bio-Rad Laboratories, Inc. (Hercules, CA/USA), a multinational manufacturer and distributor of life science research and clinical diagnostic products. The transaction is subject to ...

Further information
2009 ADHOC
23.10.2009

News: Biotest agrees to sell its Medical Diagnostics business to Bio-Rad Biotest AG:

Biotest agrees to sell its Medical Diagnostics business to Bio-Rad * Even stronger focus on plasma protein business and the clinical development of biotherapeutics * Transaction is expected to close in Q1 2010; purchase price amounts to EUR45 million Dreieich, 23 October 2009. Biotest AG announced today that it has signed an agreement to sell major parts of its Medical Diagnostics ...

Further information
2009 CORPORATE
20.10.2009

News: Biotest AG: Monoclonal antibody BT-061 shows efficacy in patients with rheumatoid arthritis

Monoclonal antibody BT-061 shows efficacy in patients with rheumatoid arthritis * Unblinded data from analysis of 40 patients in a clinical Phase II trial indicates efficacy and good tolerability * Positive response rates at week 9 (after 8-week treatment) in patients receiving treatment with BT-061 in combination with methotrexate (MTX) Dreieich, 20th October 2009. In the unblinded ...

Further information
2009 CORPORATE
30.09.2009

News: Biotest AG: Clinical development of BT-063 started

Clinical development of BT-063 started - Monoclonal antibody for the lead indication systemic lupus erythematosus - Phase I clinical trial with 24 healthy volunteers started - All three antibodies in the Biotest pipeline now in clinical development Dreieich, 30 September 2009. Biotest AG has achieved a further milestone in the development of monoclonal antibodies (mAb). The antibody BT-063 ...

Further information
2009 CORPORATE
28.09.2009

News: Biotest AG: Biotest AG receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for approval of Zutectra across the EU

Dreieich, 28 September 2009. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion for approval of Biotest's hepatitis B immunoglobulin Zutectra. The positive assessment is based on the comprehensive data available to the EMEA, which was reviewed as part of the centralised approval procedure. In the next step, this ...

Further information
2009 CORPORATE
12.08.2009

News: Biotest AG:Biotest remains successful

Biotest remains successful § Sales and EBIT in the first half of 2009 significantly increased compared to previous year's figures § Important progress made in R&D projects Dreieich, 12 August 2009. The Biotest Group once again reported profitable growth in the first half of 2009. The company which specialises in pharmaceuticals, biotherapeutics and diagnostics reported sales of ...

Further information
2009 CORPORATE
12.08.2009

Adhoc: Biotest AG: Ad-hoc RELEASE; Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG)

Dreieich, August 12, 2009. The Company is in discussions to sell its business division 'Medical Diagnostics', which essentially consists of the Biotest Medical Diagnostics GmbH in Dreieich and the Biotest Diagnostics Corporation in Rockaway/ USA. The discussions are getting more focussed now. Exclusive negotiations to sell the business division will be conducted with one particular party ...

Further information
2009 ADHOC
07.07.2009

News: Biotest AG: Further interim analyses confirm good clinical efficacy of the BT-061 monoclonal antibody.

Further interim analyses confirm good clinical efficacy of the BT-061 monoclonal antibody. - Marked improvement in symptoms even after short period of treatment - Over 240 individuals treated with BT-061 Dreieich, 7 July 2009. After the ongoing clinical development in the indication of psoriasis has provided evidence of the efficacy of the BT-061 monoclonal antibody, this has now also been ...

Further information
2009 CORPORATE
15.05.2009

News: Biotest AG: Successful Start into 2009

Successful Start into 2009 · Sales and EBIT significantly increased compared to the first quarter in the previous year · Operating basis broadened by expansion of capacity and additional approvals Dreieich, 15 May 2009. Financial year 2009 started well for Biotest Group. In the first quarter, the company, which specialises in pharmaceuticals, biotherapeutics and diagnostics, recorded ...

Further information
2009 CORPORATE
07.05.2009

Adhoc: Biotest AG: Press Release- Biotest AG: 'Biotest sales and EBIT growth in first quarter; extension of credit facility'

Press Release- Biotest AG: 'Biotest sales and EBIT growth in first quarter; extension of credit facility' - Q1 2009: Revenue Growth of 13% and EBIT increase of 8% - Extension of Credit facility Dreieich/ Frankfurt am Main, May 7, 2009 - In his speech at the Annual General Meeting today, the Chairman of the Management Board, Prof. Dr. Gregor Schulz announced sales and earnings before ...

Further information
2009 ADHOC
07.05.2009

News: Biotest AG: Annual General Meeting: Shareholders Approve Dividend of EUR 0,30 per Ordinary Share and EUR 0,36 per Preference Share

Annual General Meeting: Shareholders Approve Dividend of EUR 0,30 per Ordinary Share and EUR 0,36 per Preference Share Dreieich/ Frankfurt am Main, May 7, 2009 - Shareholders of Biotest AG with 79,11% of shareholder present, approved a dividend of EUR 0.30 per ordinary share for 2008 and a dividend of EUR 0.36 per preference share at the company's Annual General Meeting held today in ...

Further information
2009 CORPORATE
07.04.2009

News: Biotest AG: Expansion of product offering and capacity

Expansion of product offering and capacity - Immunoglobulin Hepactect(R) CP approved for additional European countries - Approval of a second immunoglobulin production plant - Annual production capacity doubled to four tonnes Dreieich, 7 April 2009. The Biotest Group has expanded the sales and marketing base for its plasma proteins business and increased the production capacity. Hepatitis B ...

Further information
2009 CORPORATE
11.03.2009

News: Biotest AG: Successful Financial Year 2008

Successful Financial Year 2008 - Sales up 29.6 % to EUR 423.0 million, with exceptional increase in EBIT - Internationalisation and R&D projects on schedule - Outlook 2009: 10% increase in sales, with EBIT on previous year's level Dreieich, 11 March 2009. The Biotest Group announced its final figures for 2008 today. The Pharmaceutical and Diagnostics group has recorded a 29.6% increase ...

Further information
2009 CORPORATE
11.02.2009

News: Biotest AG: Biotest acquires further plasmapheresis centre

Biotest acquires further plasmapheresis centre - Station in the USA with annual collection capacity of 40,000 litres - Number of centres operated by Biotest rises to 21 - Independence and resources secured through high level of self-sufficiency Dreieich, 11 February 2009. Biotest has acquired a further plasmapheresis centre in the USA. US subsidiary Biotest Pharmaceuticals Corporation ...

Further information
2009 CORPORATE
04.02.2009

Adhoc: Biotest AG: Biotest records significant growth in sales and earnings,

Biotest records significant growth in sales and earnings, Majority shareholder terminates discussion about shares' sale Dreieich, 4 February 2009. According to preliminary and unaudited figures, the Biotest Group recorded sales of EUR 423 million in financial year 2008, representing an increase of 30% on the previous year (EUR 326.4 million). Earnings before interest and tax (EBIT) are in the ...

Further information
2009 ADHOC
03.02.2009

AFR: Biotest AG: Announcement according to Articles 37v, 37w, 37x et seqq. of the WpHG [the German Securities Act] with the objective of Europe-wide distribution

Biotest AG hereby announces that the following financial reports shall be disclosed: Report: Annual financial report Date of disclosure / German: March 23, 2009 Date of disclosure / English: March 23, 2009 German: http://irpages.equitystory.com/download/Companies/biotest/Annual%20Reports/Biotest_Einzelabschluss2008.pdf English: Report: Annual financial report of the group Date of ...

Further information
2009 AFR
21.01.2009

News: Biotest AG: Cooperation secures additional plasma protein capacity

Cooperation secures additional plasma protein capacity - Biotest agrees increased utilisation of CAF-DCF fractionation capacity - Agreement to run for ten years - Annual Biotest capacity now rises to 1.4 million litres Dreieich, 21 January 2009. Biotest has considerably expanded its plasma fractionation capacity and broadened its basis for future growth by signing a further cooperation ...

Further information
2009 CORPORATE
12.01.2009

News: Biotest AG: Expansion of plasma protein product range

Expansion of plasma protein product range - Approval for Albiomin 5% and Albiomin 20% in European core markets - Preparation for use in acute medicine - Possibility of more efficient use of plasma as a raw material Dreieich, 12 January 2009. Biotest has been granted approval by the responsible authorities for the albumin preparations Albiomin 5% and Albiomin 20% under the European Mutual ...

Further information
2009 CORPORATE
15.12.2008

News: Biotest AG: Enhanced property rights for BT-062

Enhanced property rights for BT-062 - European Commission grants Orphan Drug designation to the monoclonal antibody - Designation ensures ten years' market exclusivity in the EU from approval of the drug for the treatment of multiple myeloma - Phase I clinical trials underway Dreieich, 15 December 2008. The European Commission has granted Biotest's monoclonal antibody BT-062 Orphan ...

Further information
2008 CORPORATE
10.12.2008

News: Biotest AG: European approval for Haemonine(R)

European approval for Haemonine(R) - Coagulation factor IX approved in the most important European markets - Preparation for the treatment of type B haemophilia completes product spectrum - Possibility of more efficient use of plasma as a raw material Dreieich, 10 December 2008. Biotest has taken another step forward in the continued development of its plasma protein business. The ...

Further information
2008 CORPORATE
10.12.2008

News: Biotest AG: Biotest expands plasma recovery capacities

Biotest expands plasma recovery capacities - New plasmapheresis centre in Nordhausen - Number of stations operated by Biotest rises to 19 worldwide - High degree of self-sufficiency makes Biotest more independent of global market Dreieich, 10. December 2008. Biotest AG has expanded its own capacities for obtaining raw material for its fast-growing plasma protein business. The company ...

Further information
2008 CORPORATE
28.10.2008

Adhoc: Biotest AG: Majority shareholder of Biotest AG in discussions about selling shares

Biotest AG: Majority shareholder of Biotest AG in discussions about selling shares Dreieich, the 28th of October 2008: The majority shareholder of Biotest AG, OGEL GmbH, informed the management board that OGEL GmbH is in discussions to dispose of parts of its share package. OGEL GmbH wishes to negotiate a transaction in close coordination with the management board of the company. According to ...

Further information
2008 ADHOC
17.10.2008

News: Biotest AG: Biotest: proceeding successfully

Biotest: proceeding successfully · Sales and EBIT for the first nine months considerably higher than the figures for the previous year · Board of Management confirms targets for the year as a whole · Financing secured through long-term credit lines Dreieich, 17 October 2008. Financial year 2008 is continuing to proceed extremely successfully for the Biotest Group. According to ...

Further information
2008 CORPORATE
22.09.2008

News: Biotest AG: Biotest: Promising start of clinical trial with BT062

Biotest: Promising start of clinical trial with BT062 - Monoclonal antibody was generally well tolerated at the first dose level - Clinical study in indication multiple myeloma can proceed as planned - High medical need Dreieich, September 22nd, 2008. Treatment of first patients with BT-062 commenced in the US. The drug - which is developed in the indication of multiple myeloma - was ...

Further information
2008 CORPORATE
18.08.2008

News: Biotest AG: Biotest: US approval increases potential of diagnostic business

Biotest: US approval increases potential of diagnostic business · FDA authorises marketing of manual reagents for blood group typing · Biotest consequently consolidates its position in the world's largest and most attractive market · Objective: annual sales of around US$50 million within five years Dreieich, 18 August 2008. Biotest has made significant progress in ...

Further information
2008 CORPORATE
07.08.2008

News: Biotest AG: Biotest strengthens self-sufficiency in Plasma Proteins

Biotest strengthens self-sufficiency in Plasma Proteins · Opening of new plasmapheresis centres in the USA, Germany and Hungary · Consequently, Biotest will operate 20 of its own centres worldwide this year · Self-sufficiency rate target of 50% Dreieich, 7 August 2008. Biotest is significantly expanding its capacities for obtaining blood plasma, the raw material used in the production ...

Further information
2008 CORPORATE
29.07.2008

News: Biotest AG: Biotest awarded patent protection in the USA

Biotest awarded patent protection in the USA · Patent prosecution for BT-061 successfully completed by US authorities · Decision confirms innovative character of the monoclonal antibody · Comprehensive protection against generic drugs Dreieich, 29 July 2008. Biotest's BT-061 monoclonal antibody has been recognised as an innovative development and awarded comprehensive patent protection in ...

Further information
2008 CORPORATE
18.07.2008

Adhoc: Biotest AG: strong first half year, profit target raised

Biotest: strong first half year, profit target raised Dreieich, 18 July 2008. According to preliminary figures, in the first half of 2008 Biotest achieved sales of EUR210.9 million, which represents a 33% increase year-on-year (EUR158.4 million). Earnings before interest and tax (EBIT) rose 52% to EUR27.6 million (2007: EUR18.2 million). At EUR14.4 million, Biotest's earnings after tax were ...

Further information
2008 ADHOC
27.05.2008

Adhoc: Biotest AG: Forecast for turnover and profit raised

Biotest: Forecast for turnover and profit raised Dreieich, 27 May 2008. The Managing Board of Biotest AG raised the company's forecast for turnover and profit in the current year. The Management now expects sales of EUR 420 million in 2008, following EUR 326.4 million in the previous year. Until now the target had been EUR 400 million. Earnings before interest and tax (EBIT) are expected to ...

Further information
2008 ADHOC
27.05.2008

News: Biotest AG: Payout of dividends increased, forecast improved

Biotest: Payout of dividends increased, forecast improved · General meeting finalises fifth dividend increase in a row · Managing Board raises forecast considerably for the current year · Goals for 2008: Turnover of EUR 420 million, 20% EBIT growth Dreieich, May 27, 2008. At today's general meeting of Biotest AG in Frankfurt/Main, shareholders approved of the suggestion by the Managing Board ...

Further information
2008 CORPORATE
16.05.2008

News: Biotest AG: Successful start into the Year 2008

Biotest AG: Successful Start into 2008 - Q1 Sales of EUR 105.5 million: 39% higher than in the same period of last year - Operating profit (EBIT) increased to EUR 13.3 million compared to EUR 8 million in Q1 2007 Dreieich, 16 May 2008. Financial year 2008 started well for Biotest Group. In the first quarter, the company, which specialises in pharmaceuticals, biotherapeutics and ...

Further information
2008 CORPORATE
05.05.2008

News: Biotest AG: research into additional indications for monoclonal antibody BT-061

Biotest: research into additional indications for monoclonal antibody BT-061 - Research cooperation agreed with the University of Mainz for BT-061 - Biotest's industrial property rights extended - Rheumatoid arthritis and psoriasis trials are progressing as planned Dreieich, 5 May 2008. The Biotest Group and Johannes Gutenberg University in Mainz have concluded an agreement which grants ...

Further information
2008 CORPORATE
14.04.2008

News: Biotest AG: European approvals expand the market potential for plasma proteins

Biotest: European approvals expand the market potential for plasma proteins · Factor VIII product Haemoctin(TM) and immunoglobulin Hepatect(TM) approved for use in additional countries · Synergies generated for sales and marketing · Further European approvals expected in the current year Dreieich, 14 April 2008. The Biotest Group has achieved further milestones to promote the ...

Further information
2008 CORPORATE
07.04.2008

News: Biotest AG: Biotest: Successful launch of plasma protein business in the USA

Biotest: Successful launch of plasma protein business in the USA · Work to integrate the activities acquired from Nabi Biologics in December 2007 is on schedule · Preparations for a capacity expansion have been completed · Sales and income in the first quarter match expectations Dreieich, 7 April 2008. The Biotest Group has successfully completed its first quarter as a plasma protein ...

Further information
2008 CORPORATE
11.03.2008

News: Biotest AG: Biotest achieves major milestones in the development of biotherapeutics

Biotest achieves major milestones in the development of biotherapeutics · Orphan drug designation granted for monoclonal antibody, BT-062, in the USA · Up to seven years' market exclusivity from approval · Clinical testing for indication multiple myeloma anticipated to start in the first six months of 2008 Dreieich, 11 March 2008. Biotest has achieved some further major milestones in ...

Further information
2008 CORPORATE
22.02.2008

Adhoc: Biotest AG: Biotest marked increase in sales and earnings recorded in 2007

Biotest marked increase in sales and earnings recorded in 2007 Dreieich, 22 February 2008. The Biotest Group recorded sales totalling EUR 326.4 million in financial year 2007, according to preliminary figures, which is 15.8% up on the figure for the previous year (EUR 281.9 million). Earnings before interest and tax (EBIT) rose by 22.6% to EUR 38.5 million (2006: EUR 31.4 million). The EBIT ...

Further information
2008 ADHOC
22.02.2008

News: Biotest AG: 2007 a very successful year for Biotest

2007 a very successful year for Biotest · Sharp increases in sales and earnings · Plasma proteins reach a new level · Strategic restructuring of Diagnostics continues · Biotherapeutics: clinical development of BT-061 yields positive data Dreieich, 22 February 2008. The Biotest Group recorded a marked increase in sales and earnings in financial year 2007. According to preliminary figures, for ...

Further information
2008 CORPORATE
05.12.2007

News: Biotest AG:Biotest successfully completes acquisition of Nabi Biologics assets

Biotest successfully completes acquisition of Nabi Biologics assets · Reduced net borrowings due to favourable dollar exchange rate · Management team for US plasma protein business determined · Sustainable structure for European pharmaceutical activities achieved Boca Raton/Dreieich, 5 December 2007. Biotest AG has successfully completed the first step in the acquisition of the plasma ...

Further information
2007 CORPORATE
09.11.2007

News: Biotest AG: Nabi shareholders approve sale of Biologics Business Unit to Biotest

Nabi shareholders approve sale of Biologics Business Unit to Biotest · Transfer of almost 500 employees planned for December · New syndicated loan agreement signed Boca Raton / Dreieich, 9 November 2007. At the Annual Shareholders' Meeting held yesterday in Maryland, the shareholders of Nabi Biopharmaceuticals Corp., Boca Raton (Florida, USA), approved the sale of the Biologics Business Unit ...

Further information
2007 CORPORATE
05.11.2007

News: Biotest AG: Biotest: plasmapheresis centre in Dortmund opens

Biotest: plasmapheresis centre in Dortmund opens · Seventh centre operated by the Group to obtain blood plasma in Germany · Following the acquisition of Nabi, 17 collection stations worldwide · Operation of own donor centres secures long-term supply of high quality plasma Dreieich, 5.November 2007. PlasmaService Europe, a subsidiary of Biotest AG, Dreieich, has today opened a new ...

Further information
2007 CORPORATE
21.09.2007

Adhoc: Biotest AG:Biotest successfully concludes 10% capital increase

Biotest successfully concludes 10% capital increase Dreieich, 21 September 2007. Biotest AG, Dreieich has increased its share capital by 10%. The 599,567 new ordinary shares and 466,666 new preference shares were placed through an accelerated bookbuilding process and under the exclusion of subscription rights among institutional shareholders. With an issue price of EUR 32.70 per ordinary ...

Further information
2007 ADHOC
11.09.2007

News: Biotest AG:Biotest AG acquires plasma protein business unit from Nabi Biopharmaceuticals Corp.

Biotest AG acquires plasma protein business unit from Nabi Biopharmaceuticals Corp. · Acquisition of FDA-certified pharmaceutical production facilities and nine plasmapheresis centres · Immediate strong presence in the USA with hyperimmunoglobulins and plasma raw material · Strong sales and earnings growth expected in the medium term based on new market approvals of immunoglobulins · ...

Further information
2007 CORPORATE
11.09.2007

Adhoc: Biotest AG:Biotest AG acquires plasma protein unit from Nabi Biopharmaceuticals Corp.

Biotest AG acquires plasma protein unit from Nabi Biopharmaceuticals Corp. Dreieich, 11 September 2007. Biotest AG, Dreieich has acquired the Biologics business unit ('Nabi Biologics') from Nabi Biopharmaceuticals Corp., Boca Raton (Florida, USA) in which the company's plasma protein operations are pooled, including the company's headquarters. The purchase price stands at USD 185 million ...

Further information
2007 ADHOC
10.08.2007

News: Biotest AG: Biotest remains on course for growth

Biotest remains on course for growth · Clear rise in sales and earnings in the first half of 2007 · Sustained dynamic trend in plasma proteins · Measure to increase earnings in the Diagnostic segment · Key milestones achieved in R&D projects Dreieich, 10 August 2007. The Biotest Group today published its half-year report as of 30 June 2007. With an increase in sales of 15.5% to EUR ...

Further information
2007 CORPORATE
01.08.2007

News: Biotest AG:Biotest and Abbott cooperate on a clinical trial for the expansion of the indication of Cytotect(TM)

Biotest and Abbott cooperate on a clinical trial for the expansion of the indication of Cytotect(TM) · Trial with more than 20,000 participants for the approval of the immunoglobulin in the indication connatal CMV infection · Abbott acts as diagnostics partner · Approval would result in a substantial increase in market potential for Biotest. Dreieich, 1 August 2007. Biotest AG, Dreieich, ...

Further information
2007 CORPORATE
19.07.2007

Adhoc: Biotest AG: Biotest significantly increases sales and earnings target for 2007

Dreieich, 19 July 2007. According to provisional figures, the Biotest Group recorded sales totalling EUR 158.4 million in the first six months of 2007, outperforming the previous year's figure (EUR 137.2 million) by 15.5%. Earnings before interest and tax (EBIT) amounted to EUR 18.2 million, which is 27.3% up on the comparative figure of EUR 14.3 million in 2006. The Pharmaceutical segment ...

Further information
2007 ADHOC
16.07.2007

News: Biotest AG: New clinical results increase market potential of Cytotect(TM)

New clinical results increase market potential of Cytotect(TM) · Scientific study: administration of CMV- immunoglobulins reduces risk of tumour diseases following transplants · Data of more than 40,000 patients analysed · Transplant doctors discuss practice consequences Dreieich, 16 July 2007. The indication range of Biotest's immunoglobulin, Cytotect(TM), may be expanded. An article ...

Further information
2007 CORPORATE
25.06.2007

News: Biotest AG: Biotest achieves further milestones in its monoclonal antibody development

Biotest achieves further milestones in its monoclonal antibody development · Phase I clinical trial confirms good tolerability profile of BT-061. · Start of production for the clinical testing of BT-062. Dreieich, 25 June 2007. The monoclonal antibody BT-061, developed by Biotest AG, Dreieich, has demonstrated a very good tolerability profile in a recently completed Phase I clinical study. ...

Further information
2007 CORPORATE
15.06.2007

News: Biotest receives go-ahead to export culture media to the USA

Biotest receives go-ahead to export culture media to the USA · Affiliate heipha is granted certification for the export of culture media · Focus on hygiene monitoring in the pharmaceutical industry · Biotest Diagnostics Corporation launched sales this week Dreieich/Eppelheim/Denville, 15 June 2007. The Biotest Group has taken a key step forward in the expansion of its diagnostic business in ...

Further information
2007 CORPORATE
03.05.2007

News: Biotest AG: successful start to 2007

Biotest AG: successful start to 2007 - Q1 sales 12 % higher than in the same period of the previous year - With a 16 % rise, earnings grow faster than sales - Measures have been introduced to improve earnings situation in the diagnostic segment Dreieich, 3 May 2007. Financial year 2007 has started well for Biotest Group. In the first quarter, the company, which specialises ...

Further information
2007 CORPORATE
13.03.2007

News: Biotest AG: Board of Management and Supervisory Board propose 82% dividend increase

Biotest AG: Board of Management and Supervisory Board propose 82% dividend increase - Planned dividend of EUR 0.24 per ordinary share and EUR 0.30 per preference share - Total distribution payment up from almost EUR 1.6 million to more than EUR 2.8 million - Contract of the Chairman of the Board, Professor Dr. Gregor Schulz, extended by five years Dreieich, 13 March 2007. The Board of ...

Further information
2007 CORPORATE
14.02.2007

Adhoc: Biotest AG: Increase in sales and earnings in financial year 2006 higher than expected

Increase in sales and earnings in financial year 2006 higher than expected Dreieich, 14 February 2007. According to unaudited figures, Biotest Group sales were 18.7% up on the previous year (EUR 237.6 million) to EUR 281.9 million. At EUR 31.4 million, earnings before interest and taxes (EBIT) were 24.1% higher than in financial year 2005 (EUR 25.3 million), with an improvement in profit ...

Further information
2007 ADHOC
04.01.2007

News: Biotest AG: Orphan drug status for Cytotect(TM) in the USA

The decision of the US approval authority (FDA) ensures seven years' of exclusive market access to the treatment of cytomegalovirus infections in pregnancy. Biotest estimates that the additional market potential for this new indication will amount to EUR 70 million per year. Dreieich, 5 January 2007. The US Food and Drug Administration (FDA) has granted orphan drug status to Biotest's ...

Further information
2007 CORPORATE
21.12.2006

News: Biotest AG: Major milestones achieved in the development of monoclonal antibodies. - Commencement of clinical development of BT-061.

Major milestones achieved in the development of monoclonal antibodies. - Commencement of clinical development of BT-061. Approval by regulatory authority to begin clinical development with BT-061. Impressive efficacy of BT-062 in several animal models for Multiple Myeloma - manufacturing agreement with CMC Biopharmaceuticals to provide antibody for clinical trials. Dreieich, December 21, ...

Further information
2006 CORPORATE
14.11.2006

News: Biotest AG: Biotest confirms sales and earnings target following good third quarter

Biotest confirms sales and earnings target following good third quarter Sales up 17.5% after nine months, EBIT up 19% year-on-year / Strong growth in plasma protein business / Focus in Diagnostics on immunology and microbiology / According to positive new data, clinical trials imminent in Biotherapeutics / Orphan drug status approved for Cytotect(TM) Dreieich, 14 November 2006. Biotest AG, ...

Further information
2006 CORPORATE
02.11.2006

News: Biotest AG:Biotest obtained approval for improved Hepatect(TM) product in six European countries

Marketing of the preparation for hepatitis prophylaxis is planned for this year. Modern manufacturing procedures will facilitate a higher degree of product purity and optimum use of raw materials. Dreieich, 2 November 2006. The immunglobulin Hepatect(TM) manufactured by Biotest using modern filter aid procedures, can now be marketed in six European countries. The responsible authorities in ...

Further information
2006 CORPORATE
20.10.2006

News: Biotest AG: Biotest Diagnostics Corporation Announces Appointment of Vice President, Transfusion Diagnostics

Biotest Diagnostics Corporation Announces Appointment of Vice President, Transfusion Diagnostics Denville, NJ / Dreieich, 20 October 2006. Biotest Diagnostics Corporation (BDC), a subsidiary of Biotest AG, a worldwide supplier of manual and automated solutions to the blood bank industry, announces the appointment of Candace K. Williams to the newly created position of Vice President ...

Further information
2006 CORPORATE
20.10.2006

News: Biotest AG: New Automated Assays for TANGO(TM) Automated Blood Bank Systems under Food and Drug Administration Review

New Automated Assays for TANGO(TM) Automated Blood Bank Systems under Food and Drug Administration Review Denville, NJ, 20 October 2006. Biotest Diagnostics Corporation (BDC), subsidiary of Biotest AG, a worldwide supplier of manual and automated solutions to the blood bank industry, announced today that it made Biologic License Applications and 510(k) premarket notifications to the U. S. ...

Further information
2006 CORPORATE
20.10.2006

News: Biotest AG: Biotest announces important Milestone for Full Line of Manual Blood Bank Reagents

Biotest announces important Milestone for Full Line of Manual Blood Bank Reagents Denville, NJ / Dreieich, 20 October 2006. Biotest Diagnostics Corporation (BDC), subsidiary of Biotest AG, a worldwide supplier of manual and automated solutions to the blood bank industry, announced today that it has made Biologic License Applications and 510(k) premarket notification submissions to the U.S. ...

Further information
2006 CORPORATE
20.10.2006

News: Biotest AG: Olympus and Biotest redefine distribution relationship for Tango(TM) systems

Olympus and Biotest redefine distribution relationship for Tango(TM) systems Center Valley, PA / Dreieich, 20 October 2006. Olympus America Inc. and Biotest AG of Germany have redefined the agreement under which Biotest's TANGO(TM) Automated Blood Bank systems will be sold, serviced and supported throughout the U.S. Under the new relationship, Biotest will market TANGO directly to American ...

Further information
2006 CORPORATE
28.09.2006

Biotest AG: EMEA Committee in favour of Orphan Drug status for Cytotect(TM)

EMEA Committee in favour of Orphan Drug status for Cytotect(TM) Large market potential for treatment of cytomegalovirus infections during pregnancy / Europe-wide authorisation study to begin at the start of 2007 / Good chances of Orphan Drug status in the USA too / Positive reactions from Gynaecologists and private health insurers Dreieich, 28 September 2006. The hyperimmunoglobuline, ...

Further information
2006 CORPORATE
14.08.2006

Biotest AG: Continuing growth

Biotest AG: Continuing growth · First half year of 2006: Sales rise by 19.1% to EUR137.2 million, an even more marked increase in operating profit than in sales · Success from coagulation agents and immunoglobulins · Contract with ImmunoGen a key milestone in the development of biotherapeutics Dreieich, 14 August 2006. In the first half-year of 2006, the Biotest Group achieved sales of ...

Further information
2006 CORPORATE
11.07.2006

BiotBiotest secures exclusive rights to ImmunoGen's world leading cytotoxic agent technologyest AG:

Biotest secures exclusive rights to ImmunoGen's world leading cytotoxic agent technology Collaboration and licensing agreement with ImmunoGen secures future global sales of cancer therapy based on the BT-062 antibody. Option for joint development in the USA - license payments dependent on milestones Cambridge, MA/Dreieich, July 11, 2006. Biotest AG, Dreieich, has secured, via a ...

Further information
2006 CORPORATE
11.05.2006

Biotest AG:Good start to 2006 - a year of growth: Group sales up by 21%, overproportional growth recorded in earnings

Good start to 2006 - a year of growth: Group sales up by 21%, overproportional growth recorded in earnings Strong increases in immunoglobulins and coagulative agents - sales and earnings target for financial year 2006 as a whole confirmed Dreieich/Frankfurt/Main, 11 May 2006. Biotest AG, Dreieich, achieved Group sales of EUR 67.5 million in the first quarter of 2006, which represents ...

Further information
2006 CORPORATE
11.05.2006

Biotest AG: Stock option programme fails to achieve required majority

Biotest AG: Stock option programme fails to achieve required majority from preferred shareholders Dreieich/Frankfurt/Main, 11 May 2006. With 83.46% of shareholders present, the Annual General Meeting of Biotest AG, Dreieich, today approved by a large majority (94.64%) the creation of conditional capital amounting to EUR 0.98 million to secure subscription rights under a company stock ...

Further information
2006 CORPORATE
03.05.2006

Biotest AG:Biotest and Sanquin plan a strategic alliance in plasma products

Biotest and Sanquin plan a strategic alliance in plasma products Amsterdam/ Dreieich, 3 May 2006. Collaborating successfully for over 20 years already, Biotest AG, Dreieich, Germany and the Sanquin Blood Supply Foundation ("Sanquin"), Amsterdam, The Netherlands now plan to pool their activities in the area of producing and developing plasma products. Parties have agreed to enter into ...

Further information
2006 ADHOC
22.03.2006

Biotest AG:Supervisory Board announces early extension of Dr. Michael Ramroth's (CFO), contract by five years

Supervisory Board announces early extension of Dr. Michael Ramroth's (CFO), contract by five years Dreieich, 21 March 2006. The Supervisory Board of Biotest AG, Dreieich, extended the contract of Dr. Michael Ramroth (44), which was originally due to expire in February 2007, by a further five years. Dr. Ramroth is responsible for Finance and Central Services (including Legal and ...

Further information
2006 CORPORATE
22.03.2006

Biotest AG:"Focused research, global growth": Biotest increases its market share worldwide and announces ambitious targets for 2006

"Focused research, global growth": Biotest increases its market share worldwide and announces ambitious targets for 2006 Intratect sales to treble by 2007 - high level of demand for immunoglobulins results in planned capacity expansion to 4,000 kg - aim is to achieve orphan drug status for Cytotect(TM) in the European Union Dreieich, Frankfurt/Main, 21 March 2006. Biotest AG, ...

Further information
2006 CORPORATE
17.02.2006

Biotest AG: Successful financial year 2005: Biotest increases sales, doubles the result and reduces financial liabilities

Successful financial year 2005: Biotest increases sales, doubles the result and reduces financial liabilities Double-digit return on sales before interest and taxes - Strong growth in pharmaceutical business - Turnaround in diagnostics - Development of biotherapeutic products as planned Dreieich, 17 February 2006. Significant increase in sales, above average improvement in the result, ...

Further information
2006 CORPORATE